???global.info.a_carregar???
The research line of Dr. Pedro M. Rodrigues has been focused on basic research applied to translational medicine, mainly in liver pathophysiology. During his Doctoral Thesis, at the University of Lisbon (2013-2017), he was interested in studying the role of miRNA-21 in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). In July 2017, he obtained his PhD in Pharmacy, from the University of Lisbon (Portugal) with the maximum qualification (Excellent “Cum Laude”). In March 2018, Dr. Rodrigues joined the Liver Diseases Group led by Dr. Banales (BHRI) to conduct his post-doctoral studies. In the end of 2019, he obtained Sara Borrell postdoctoral contract, from the Carlos III Health Institute (ISCIII). During this period, he started to create and led his own lines of research, mostly focused on the development and progression of metabolic liver diseases and cancer. This fact was reinforced after obtaining the competitive IKERBASQUE Research Fellow (Basque Foundation of Science) in July 2021 (2021-2026), which has given him the stability to carry lead his own research projects. More recently (end of 2022), he obtained the competitive Miguel Servet contract, which allowed to him to undoubtedly establish as an independent PI in the Liver Diseases Group, creating and leading his own research lines. During his research career, he published 58 manuscripts (h-index: 22; 4676 citations; 10 manuscripts as senior/corresponding author) in top scientific journals in his field of research (New England Journal of Medicine, Nat Rev Gastroenterol Hepatol, Nature, J Hepatol, Annu Rev Pathol, Gut, Hepatology, among others). Regarding student supervision and leadership skills, he has supervised 2 master students and 4 PhD students and he is currently supervising 2 master students, 4 doctoral students and 1 post-doctoral researcher. Notably, he is PI in active research projects funded by National and International Institutions (Total Number of Projects funded as PI: 12 projects: 1.241.608€). Notably, as Associate Investigator, he participates in more than 20 national and international projects funded with a total of 5.3 M€. Regarding knowledge transfer, he is collaborating with national and international pharmaceutical and R&D companies, such as OWL Metabolomics, Albireo Pharma, Incyte Pharma, among others, in the development of new bio-sanitary products that are generating wealth (patents or companies). He received several prestigious awards, including the National Scholar Award, from the European Gastroenterology Union (UEG), the UEG Rising Star 2022 from the UEG Association, which distinguishes young (<40 y/o) emerging leaders in the field of gastroenterology and also the AEEH Rising Star Award 2024. He is also Management Committee Member at: (1) the European Network for the Study of Cholangiocarcinoma (ENSCCA) and (2) the Precision-BTC-Network (EU H2020; WG2 Leader). Currently, he is member of the EASL Young Investigator Task Force (2023-2026). He is also Associate Editor of Frontiers in Pharmacology (IF. 5.8) and I am member of the Editorial Reviewer Board of Cancers (IF. 6.6) and Hepatology Communications (IF. 5.7). At the moment, he is Leader of the Metabolism & Cancer Group, at BHRI and Miguel Servet I Investigator (ISCIII), CIBERehd researcher and IKERBASQUE Research Fellow. His current scientific interests are based on the study of the molecular mechanisms that govern liver diseases, mainly NAFLD and cholangiocarcinoma, trying to unravel new diagnostic tools, prognosis and also relevant therapeutic targets.
Ler resumo completo ↓
Identificação

Identificação pessoal

Nome completo
Pedro Rodrigues

Nomes de citação

  • Rodrigues, Pedro

Identificadores de autor

Ciência ID
2716-88AB-CB82
ORCID iD
0000-0001-6193-7436

Endereços de correio eletrónico

  • pedromiguel.rodriguesvieira@bio-gipuzkoa.eus (Profissional)

Domínios de atuação

  • Ciências Médicas e da Saúde

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Inglês Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1)
Português Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1)
Espanhol; Castelhano Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1)
Formação
Grau Classificação
2017
Concluído
 Farmácia (Doutoramento)
Universidade de Lisboa Faculdade de Farmácia, Portugal
"A Role for miRNA-21 in non-alcoholic fatty liver disease pathogenesis" (TESE/DISSERTAÇÃO)
 Aprovado com Louvor e Distinção
2012
Concluído
 Curso de Especialização em Ciências Biofarmacêuticas (60 ECTS) - Ano curricular do Mestrado em Ciências Biofarmacêuticas (Especialização pós-licenciatura)
Universidade de Lisboa Faculdade de Farmácia, Portugal
"-" (TESE/DISSERTAÇÃO)
 18/20
2011
Concluído
 Licenciatura em Biologia Celular e Molecular (180 ECTS) (Licenciatura)
Universidade Nova de Lisboa Faculdade de Ciências e Tecnologia, Portugal
"n/a" (TESE/DISSERTAÇÃO)
 17/20
Percurso profissional

Cargos e Funções

Categoria Profissional
Instituição de acolhimento 		Empregador
2024/01/01 - Atual Head, Metabolism & Cancer Group Biogipuzkoa Health Research Institute, Espanha
2020/03/31 - Atual CIBERehd Investigator Instituto de Salud Carlos III, Espanha
2020/01/01 - 2022/12/31 Sara Borrell Post-doctoral Investigator Biodonostia Instituto de Investigación Sanitaria, Espanha

Outros

Categoria Profissional
Instituição de acolhimento 		Empregador
2023/01/01 - Atual Miguel Servet I Investigator Biodonostia Instituto de Investigación Sanitaria, Espanha
2021/09/01 - Atual Ikerbasque Research Fellow Ikerbasque, Espanha
Biodonostia Instituto de Investigación Sanitaria, Espanha
2018/03/12 - 2019/12/31 Post-doctoral Fellow Biodonostia Instituto de Investigación Sanitaria, Espanha
2017/09/11 - 2018/03/10 Post-doctoral Fellow Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
2013/03/01 - 2017/07/17 Ph.D. Student (SFRH/BD/88212/2012) Thesis: "A role for miRNA-21 in Non-alcoholic fatty liver disease pathogenesis" Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
2011/11/09 - 2013/02/28 Volunteer investigator in the group Molecular and Cell Biology of Eukaryotic Systems from Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
2009/10/01 - 2011/09/30 BII fellow - Stuctural and functional characterization of systems involved in gene regulation: the transcription regulator of orange protein operon. Rede de Química e Tecnologia Laboratório Associado para a Química Verde, Portugal
2010/08/02 - 2010/08/27 Professional training in clinic diagnosis - Molecular biology and Microbiology in clinic analyses (volunteer work) Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
Projetos

Bolsa

Designação Financiadores
2018/01/01 - Atual Non-alcoholic fatty liver disease: emerging biomarkers, targets and therapies
PTDC/MED-NEU/29455/2017
Investigador
Fundação para a Ciência e a Tecnologia
Em curso
2018/01/01 - Atual Sinalização Exossomal entre o Tecido Adiposo e Hepático no Fígado Gordo Não Alcoólico: Função e Modulação
PTDC/MED-PAT/31882/2017
Investigador
Fundação para a Ciência e a Tecnologia
Em curso
2023/10/09 - 2027/10/08 Precision medicine in biliary tract cancer (Precision-BTC-Network)
CA22125
Investigador
Biogipuzkoa Health Research Institute, Espanha
 European Cooperation in Science and Technology
Em curso
2024/01/01 - 2026/12/31 EpiCHOL: novel epigenetic players in the diagnosis, pathogenesis and treatment of non-alcoholic fatty liver disease-associated cholangiocarcinoma
PI23/01850
Investigador responsável
Biogipuzkoa Health Research Institute, Espanha
 Instituto de Salud Carlos III
Em curso
2023/12/01 - 2026/11/30 EpiNAFLD-LC: novel epigenetic players in the diagnosis, pathogenesis and treatment of non-alcoholic fatty liver disease (NAFLD)-associated liver cancer.
LABAE235286RODR
Investigador responsável
Biogipuzkoa Health Research Institute, Espanha
 Asociación Española Contra el Cáncer
Em curso
2023/09/01 - 2026/08/31 International validation of protein biomarkers for the prediction and diagnosis of cholangiocarcinoma (CCA) in patients with primary sclerosing cholangitis (PSC)
JMBPROJ23
Investigador responsável
Biogipuzkoa Health Research Institute, Espanha
 PSC Supports
Em curso
2023/01/01 - 2025/12/31 Exploring the Feasibility of predictive and pharmacodynamics biomarkers of immunotherapy in solid tumors (Immune4ALL)
PMP22/00054
Investigador
Instituto de Salud Carlos III
Em curso
2023/01/01 - 2025/12/31 Eficacia y seguridad del Ácido Ursodesoxicólico como nueva terapia para el tratamiento de las Enfermedades Hepatorrenales Poliquísticas, estudio genético y determinación de biomarcadores pronóstico (ensayo URSOPOL)
ICI22/00043
Investigador
Instituto de Salud Carlos III
Em curso
2022/12/01 - 2025/12/31 Búsqueda de biomarcadores de última generación para la predicción, diagnóstico temprano y estimación del pronóstico de pacientes con colangiocarcinoma
2022111070
Investigador responsável
Gobierno Vasco Departamento de Salud
Em curso
2021/01/01 - 2025/01/01 Enfermedades cardiometabólicas: desarrollo de estrategias diagnósticas y terapéuticas personalizadas combinando factores de riesgo y caracterización molecular
#2020111077
Investigador
Gobierno Vasco Departamento de Salud
Em curso
2023/04/19 - 2024/09/30 Papel de la SUMOilación en la etiopatogenia del cáncer biliar: nueva estrategia diagnóstica, pronóstica y terapéutica
2023-CIEN-000008-01
Investigador responsável
Biogipuzkoa Health Research Institute, Espanha
 Diputación Foral de Guipúzcoa
2023/01/01 - 2024/06/30 Role of microRNAs in immunological and cellular responses to COVID-19 vaccination in patients with chronic liver diseases (miR-HEPCOVIVac)
2022.08837.PTDC
Co-Investigador Responsável (Co-IR)
Fundação para a Ciência e a Tecnologia
Em curso
2021/01/01 - 2023/12/31 Papel del receptor scavenger MARCO en la inmuno-oncología de los tumores primarios del hígado: nueva estrategia diagnóstica, pronostica y terapéutica
PI20/00186
Investigador
Instituto de Salud Carlos III
Em curso
2022/04/01 - 2023/10/31 Role of exosomal miRNA-21 in the muscle-liver axis during non-alcoholic fatty liver disease pathogenesis
EXPL/MED-OUT/1317/2021
Investigador responsável
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
 Fundação para a Ciência e a Tecnologia
Em curso
2021/10/27 - 2023/10/27 Role of microRNAs in the etiopathogenesis and chemoresistance of cholangiocarcinoma
xxx
Investigador responsável
Biodonostia Instituto de Investigación Sanitaria, Espanha
 Asociación Española Para el Estudio del Hígado
Em curso
2020/01/01 - 2023/01/01 Exosomal fat-liver axis in non-alcoholic fatty liver disease: function and modulation
HR17-00601
Investigador
Obra Social La Caixa
Em curso
2020/01/01 - 2023/01/01 Role of the transcription factor KLF5 in the etiopathogenesis of cholangiocarcinoma: new diagnostic, prognostic and therapeutic strategy.
EU/2019/AMMFt/001
Investigador responsável
AMMF, The Cholangiocarcinoma Charity UK
Em curso
2019/01/01 - 2023/01/01 European Cholangiocarcinoma Network
OC-2018-1-22912
Investigador
Horizon 2020
Em curso
2019/01/01 - 2023/01/01 European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development
H2020-SC1-BHC-2018-2020
Investigador
Horizon 2020
Em curso
2022/01/01 - 2022/12/31 Diseño, síntesis y validación de fármacos selectivos frente a HDACs en cáncer biliar: nueva terapia epigenética
2020333032
Investigador
Gobierno Vasco Departamento de Salud
Concluído
2022/01/01 - 2022/12/31 Enfoque teranóstico integral para la fibrosis basado en nanobiotecnología
2020333041
Investigador
Gobierno Vasco Departamento de Salud
2019/12/01 - 2022/12/31 Papel del receptor scavenger MARCO en la inmuno-oncología del cáncer de hígado: nueva estrategia diagnóstica, pronostica y terapéutica.
2019111024
Investigador
Gobierno Vasco
Em curso
2021/06/07 - 2022/09/30 Búsqueda de biomarcadores de última generación para el diagnóstico temprano y estimación del pronóstico de pacientes con colangiocarcinoma.
2021-CIEN-000029-04-01
Investigador responsável
Biodonostia Instituto de Investigación Sanitaria, Espanha
 Diputación Foral de Guipúzcoa
Em curso
2020/07/13 - 2021/09/30 Role of the transcription factor KLF15 in the etiopathogenesis of cholangiocarcinoma: new diagnostic, prognostic and therapeutic strategy.
2020-CIEN-000067-01
Investigador responsável
Biodonostia Instituto de Investigación Sanitaria, Espanha
 Diputación Foral de Guipúzcoa
Em curso
2019/09/06 - 2021/09/06 Metabolomic-based Prediction of Prognosis in Patients with Primary Sclerosing Cholangitis and Early Diagnosis of Cholangiocarcinoma: New Non-invasive Strategy.
EU/2019/PSCSupport/001
Investigador
Biodonostia Instituto de Investigación Sanitaria, Espanha
 PSC Supports
Em curso
2019/06/10 - 2021/06/10 Metabolomic-based Prediction of Prognosis in Patients with Primary Sclerosing Cholangitis and Early Diagnosis of Cholangiocarcinoma: New Non-invasive Strategy.
Int/2019/PSCPartners/001
Investigador
Biodonostia Instituto de Investigación Sanitaria, Espanha
 PSC Partners Seeking a cure
Em curso
2020/01/01 - 2020/12/31 Diseño, síntesis y validación de nuevos agentes quimioterápicos frente a cánceres resistentes al cisplatino: nueva estrategia terapéutica para el colangiocarcinoma
2020333010
Investigador
Gobierno Vasco
Concluído
2019/04/05 - 2020/09 Papel del receptor scavenger MARCO en el desarrollo y progresión de los cánceres hepáticos primarios HCC y CCA
81/2019
Investigador
Diputación Foral de Guipúzcoa
Concluído
2018/04/12 - 2019/09/30 The role of TREM-2 receptor in hepatobiliary diseases and CCA pathogenesis
DFG114/18
Investigador
Diputación Foral de Guipúzcoa
Concluído
2015/01/01 - 2017/12/31 Role of mitofusin-2 in non-alcoholic fatty liver disease and targeting by miRNAs in liver disease.
--
Investigador
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
 Gilead Sciences International Ltd
Concluído
2013/07 - 2015/12 Aiming at miR-21 and bile acid-activated receptors in non-alcoholic fatty liver disease pathogenesis: two bullets for one murder?
Provided by PTCRIS: 125582
 Fundação para a Ciência e a Tecnologia, I.P.
2011/01 - 2014/07 Targeting microRNA-34, a Potential Link between Apoptosis and Nonalcoholic Fatty Liver Disease Pathogenesis
Provided by PTCRIS: 111930
 Fundação para a Ciência e a Tecnologia, I.P.

Projeto

Designação Financiadores
2022/01/17 - 2023/07/16 O papel do microRNA-21 exossomal na comunicação fígado-músculo durante o desenvolvimento e progressão de Fígado Gordo Não Alcoólico
EXPL/MED-OUT/1317/2021
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
 Fundação para a Ciência e a Tecnologia
Em curso
2017/09/11 - 2018/03/10 Targeting the NAFLD-HCC continuum with bile acid-activated receptor agonists and microRNAs.
--
Investigador Pós-doutorado
Intercept Pharmaceuticals, Inc
Concluído
2013/07/01 - 2015/12/31 Com o miR-21 e os receptores ativados pelos ácidos biliares em mira na patogénese do fígado gordo não alcoólico: duas balas para um homicídio?
PTDC/BIM-MEC/0873/2012
University of Minnesota Twin Cities Department of Medicine, Estados Unidos

The University of Texas Southwestern Medical Center, Estados Unidos

Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2011/01/03 - 2014/07/02 Modulação do microRNA-34, um Elo Potencial entre a Apoptose e a Patogénese do Fígado Gordo Não Alcoólico
PTDC/SAU-ORG/111930/2009
University of Minnesota Twin Cities Department of Genetics Cell Biology and Development, Estados Unidos

Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal

Universidade de Lisboa Faculdade de Farmácia, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
Produções

Publicações

Artigo em revista
  1. Olaizola, Paula; Olaizola, Irene; Lapitz, Ainhoa; Val, Beatriz; Izquierdo-Sanchez, Laura; Fernandez-Barrena, Maite G.; O’Rourke, Colm J.; et al. "Targeting protein hyperSUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma crosstalk". Hepatology (2025): https://doi.org/10.1097/hep.0000000000001259.
    No prelo • 10.1097/hep.0000000000001259
  2. Iturbe-Rey, Santiago; Maccali, Claudia; Arrese, Marco; Aspichueta, Patricia; Oliveira, Claudia P.; Castro, Rui E.; Lapitz, Ainhoa; et al. "Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)". Atherosclerosis 400 (2025): 119053. https://doi.org/10.1016/j.atherosclerosis.2024.119053.
    Publicado • 10.1016/j.atherosclerosis.2024.119053
  3. da Fonseca, Leonardo G.; Izquierdo-Sanchez, Laura; Hashizume, Pedro H.; Carlino, Yanina; Baca, Estefanía Liza; Zambrano, Cristina; Sepúlveda, Santiago A.; et al. "Cholangiocarcinoma in Latin America: a multicentre observational study alerts on ethnic disparities in tumour presentation and outcomes". The Lancet Regional Health - Americas 40 (2024): 100952. https://doi.org/10.1016/j.lana.2024.100952.
    Publicado • 10.1016/j.lana.2024.100952
  4. Kevin De Muynck; Lander Heyerick; Federico F. De Ponti; Bart Vanderborght; Tim Meese; Sanne Van Campenhout; Leen Baudonck; et al. "Osteopontin characterizes bile duct–associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis". Hepatology (2024): https://doi.org/10.1097/HEP.0000000000000557.
    10.1097/HEP.0000000000000557
  5. Pydyn, Natalia; Ferenc, Anna; Trzos, Katarzyna; Pospiech, Ewelina; Wilamowski, Mateusz; Mucha, Olga; Major, Piotr; et al. "MCPIP1 Inhibits Hepatic Stellate Cell Activation in Autocrine and Paracrine Manners, Preventing Liver Fibrosis". Cellular and Molecular Gastroenterology and Hepatology (2024): http://dx.doi.org/10.1016/j.jcmgh.2024.01.021.
    No prelo • 10.1016/j.jcmgh.2024.01.021
  6. Lewinska, Monika; Zhuravleva, Ekaterina; Satriano, Letizia; Martinez, Marta B.; Bhatt, Deepak K.; Oliveira, Douglas V.N.P.; Antoku, Yasuko; et al. "Fibroblast-Derived Lysyl Oxidase Increases Oxidative Phosphorylation and Stemness in Cholangiocarcinoma". Gastroenterology (2023): http://dx.doi.org/10.1053/j.gastro.2023.11.302.
    No prelo • 10.1053/j.gastro.2023.11.302
  7. Aloña Agirre-Lizaso; Maider Huici-Izagirre; Josu Urretabizkaia-Garmendia; Pedro M. Rodrigues; Jesus M. Banales; Maria J. Perugorria. "Targeting the Heterogeneous Tumour-Associated Macrophages in Hepatocellular Carcinoma". Cancers (2023): https://doi.org/10.3390/cancers15204977.
    10.3390/cancers15204977
  8. Pedro M. Rodrigues; Marta B. Afonso; André L. Simão; Tawhidul Islam; Maria M. Gaspar; Colm J. O'Rourke; Monika Lewinska; et al. "miR-21-5p promotes NASH-related hepatocarcinogenesis". Liver International (2023): https://doi.org/10.1111/liv.15682.
    10.1111/liv.15682
  9. Francisco J. Caballero-Camino; Pedro M. Rodrigues; Fredrik Wångsell; Aloña Agirre-Lizaso; Paula Olaizola; Laura Izquierdo-Sanchez; Maria J. Perugorria; et al. "A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans". Hepatology (2023): https://doi.org/10.1097/HEP.0000000000000376.
    10.1097/HEP.0000000000000376
  10. Lapitz, Ainhoa; Azkargorta, Mikel; Milkiewicz, Piotr; Olaizola, Paula; Zhuravleva, Ekaterina; Grimsrud, Marit M.; Schramm, Christoph; et al. "Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis and prognostication of cholangiocarcinoma". Journal of Hepatology (2023): http://dx.doi.org/10.1016/j.jhep.2023.02.027.
    10.1016/j.jhep.2023.02.027
  11. Ament, Cindy E.; Steinmann, Sara; Evert, Katja; Pes, Giovanni M.; Ribback, Silvia; Gigante, Isabella; Pizzuto, Elena; et al. "Aberrant fucosylation sustains the NOTCH and EGFR/NF-kB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma". Hepatology Publish Ah (2023): http://dx.doi.org/10.1097/hep.0000000000000322.
    No prelo • 10.1097/hep.0000000000000322
  12. Diego F. Calvisi; Luke Boulter; Javier Vaquero; Anna Saborowski; Luca Fabris; Pedro M. Rodrigues; Cédric Coulouarn; et al. "Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance". Nature Reviews Gastroenterology & Hepatology (2023): https://doi.org/10.1038/s41575-022-00739-y.
    10.1038/s41575-022-00739-y
  13. Markaide, Enara; Bañales, Jesús M.; Rodrigues, Pedro M.. "Polycystic liver diseases: from molecular basis to the development of effective treatments". Revista Española de Enfermedades Digestivas (2023): http://dx.doi.org/10.17235/reed.2023.9649/2023.
    10.17235/reed.2023.9649/2023
  14. Labiano, Ibone; Agirre-Lizaso, Aloña; Olaizola, Paula; Echebarria, Anne; Huici-Izagirre, Maider; Olaizola, Irene; Esparza-Baquer, Aitor; et al. "TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation". Journal of Hepatology 77 4 (2022): 991-1004. http://dx.doi.org/10.1016/j.jhep.2022.05.044.
    Publicado • 10.1016/j.jhep.2022.05.044
  15. Paula Olaizola; Pedro M. Rodrigues; Francisco J. Caballero-Camino; Laura Izquierdo-Sanchez; Patricia Aspichueta; Luis Bujanda; Nicholas F. Larusso; et al. "Genetics, pathobiology and therapeutic opportunities of polycystic liver disease". Nature Reviews Gastroenterology & Hepatology (2022): https://doi.org/10.1038/s41575-022-00617-7.
    10.1038/s41575-022-00617-7
  16. Degenhardt, Frauke; Ellinghaus, David; Juzenas, Simonas; Lerga-Jaso, Jon; Wendorff, Mareike; Maya-Miles, Douglas; Uellendahl-Werth, Florian; et al. "Detailed stratified GWAS analysis for severe COVID-19 in four European populations". Human Molecular Genetics 31 23 (2022): 3945-3966. http://dx.doi.org/10.1093/hmg/ddac158.
    Publicado • 10.1093/hmg/ddac158
  17. Garcia-Etxebarria, Koldo; Merino, Olga; Gaite-Reguero, Adrián; Rodrigues, Pedro M.; Herrarte, Amaia; Etxart, Ane; Ellinghaus, David; et al. "Local genetic variation of inflammatory bowel disease in Basque population and its effect in risk prediction". Scientific Reports 12 1 (2022): http://dx.doi.org/10.1038/s41598-022-07401-2.
    Acesso aberto • Publicado • 10.1038/s41598-022-07401-2
  18. Olaizola, Paula; Lee-Law, Pui Yuen; Fernandez-Barrena, Maite G.; Alvarez, Laura; Cadamuro, Massimiliano; Azkargorta, Mikel; O’Rourke, Colm J.; et al. "Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models". Journal of Hepatology (2022): http://dx.doi.org/10.1016/j.jhep.2022.02.007.
    No prelo • 10.1016/j.jhep.2022.02.007
  19. Rodrigues, Pedro M.; Banales, Jesus M.. "Editorial: bezafibrate in the treatment of patients with primary biliary cholangitis—are we there yet?". Alimentary Pharmacology & Therapeutics 55 2 (2021): 247-248. http://dx.doi.org/10.1111/apt.16657.
    Publicado • 10.1111/apt.16657
  20. Nakanishi, Tomoko; Pigazzini, Sara; Degenhardt, Frauke; Cordioli, Mattia; Butler-Laporte, Guillaume; Maya-Miles, Douglas; Bujanda, Luis; et al. "Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality". Journal of Clinical Investigation 131 23 (2021): http://dx.doi.org/10.1172/jci152386.
    Publicado • 10.1172/jci152386
  21. Laura Izquierdo-Sanchez; Jesus M. Banales; Pedro M. Rodrigues. "A look back at cholangiocarcinoma in Finland". United European Gastroenterology Journal (2021): https://doi.org/10.1002/ueg2.12157.
    10.1002/ueg2.12157
  22. Xinjun Lu; Baogang Peng; Ge Chen; Mario G. Pes; Silvia Ribback; Cindy Ament; Hongwei Xu; et al. "YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice". The American Journal of Pathology (2021): https://doi.org/10.1016/j.ajpath.2021.05.017.
    10.1016/j.ajpath.2021.05.017
  23. Lee-Law, Pui Y.; Olaizola, Paula; Caballero-Camino, Francisco J.; Izquierdo-Sanchez, Laura; Rodrigues, Pedro M.; Perugorria, Maria J.; Azkargorta, Mikel; et al. "Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease". United European Gastroenterology Journal 9 7 (2021): 848-859. http://dx.doi.org/10.1002/ueg2.12126.
    Publicado • 10.1002/ueg2.12126
  24. Niemi, Mari E. K.; Karjalainen, Juha; Liao, Rachel G.; Neale, Benjamin M.; Daly, Mark; Ganna, Andrea; Pathak, Gita A.; et al. "Mapping the human genetic architecture of COVID-19". Nature 600 7889 (2021): 472-477. http://dx.doi.org/10.1038/s41586-021-03767-x.
    Publicado • 10.1038/s41586-021-03767-x
  25. Pedro M. Rodrigues; Paula Olaizola; Jesus M. Banales; Rodrigues, Pedro; Olaizola, Paula; Banales, Jesus Maria. "Unscrambling a novel pathogenic role for interleukin-20 in acute hepatitis and bacterial infection: A double-edged sword?". Journal of Hepatology 75 1 (2021): 22-24. https://doi.org/10.1016/j.jhep.2021.03.011.
    Aceite para publicação • 10.1016/j.jhep.2021.03.011
  26. Pedro M. Rodrigues; Arndt Vogel; Marco Arrese; Domingo C. Balderramo; Juan W. Valle; Jesus M. Banales. "Next-Generation Biomarkers for Cholangiocarcinoma". Cancers 13 13 (2021): 3222-3222. https://doi.org/10.3390/cancers13133222.
    10.3390/cancers13133222
  27. Pedro M. Rodrigues; Jesus M. Banales. "Applications of organoids in regenerative medicine: a proof-of-concept for biliary injury". Nature Reviews Gastroenterology & Hepatology (2021): https://doi.org/10.1038/s41575-021-00459-9.
    10.1038/s41575-021-00459-9
  28. Afonso, Marta; Rodrigues, Pedro; Mateus-Pinheiro, Miguel; A. Simão; Gaspar, Maria Manuela; Majdi, A; Arretxe, Enara; et al. "RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease". Gut (2021):
    No prelo
  29. Rodrigues, Pedro M.; Olaizola, Paula; Paiva, Nuno A.; Olaizola, Irene; Agirre-Lizaso, Alona; Landa, Ana; Bujanda, Luis; Perugorria, Maria J.; Banales, Jesus M.. "Pathogenesis of Cholangiocarcinoma". Annual Review of Pathology: Mechanisms of Disease 16 1 (2021): 433-463. http://dx.doi.org/10.1146/annurev-pathol-030220-020455.
    Publicado • 10.1146/annurev-pathol-030220-020455
  30. Francisco J. Caballero-Camino; Ivan Rivilla; Elisa Herraez; Oscar Briz; Alvaro Santos-Laso; Laura Izquierdo-Sanchez; Pui Y. Lee-Law; et al. "Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease". Hepatology 73 1 (2021): 186-203. https://doi.org/10.1002/hep.31216.
    Publicado • 10.1002/hep.31216
  31. Gutiérrez-Larrañaga, María; González-López, Elena; Roa-Bautista, Adriel; Rodrigues, Pedro M.; Díaz-González, Álvaro; Banales, Jesus M.; López-Hoyos, Marcos; Santos-Laso, Alvaro; Crespo, Javier. "Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?". Liver Cancer 10 6 (2021): 545-560. http://dx.doi.org/10.1159/000518104.
    Publicado • 10.1159/000518104
  32. Cassetta, Luca; Andreu, Toni; Botta, Bruno; Brandau, Sven; Brierley, Chrissie; Wilson, Clive; Dadeshidze, Inga; et al. "Beating Cancer by 2030: Mission Impossible?". Research Ideas and Outcomes 6 (2020): http://dx.doi.org/10.3897/rio.6.e61662.
    Publicado • 10.3897/rio.6.e61662
  33. Ribeiro, Maria F; Santos, André A; Afonso, Marta B; Rodrigues, Pedro M; Sá Santos, Sónia; Castro, Rui E; Rodrigues, Cecília M P; Solá, Susana. "Diet-dependent gut microbiota impacts on adult neurogenesis through mitochondrial stress modulation". Brain Communications 2 2 (2020): http://dx.doi.org/10.1093/braincomms/fcaa165.
    Publicado • 10.1093/braincomms/fcaa165
  34. Rodrigues, Pedro. "Characterizing the Heterogeneity of Liver Cell Populations Under a NASH-Related Hepatotoxicant Using Single-Nuclei RNA Sequencing". Cellular and Molecular Gastroenterology and Hepatology (2020): http://dx.doi.org/10.1016/j.jcmgh.2020.09.005.
    10.1016/j.jcmgh.2020.09.005
  35. Jesus M. Banales; Jose J. G. Marin; Angela Lamarca; Pedro M. Rodrigues; Shahid A. Khan; Lewis R. Roberts; Vincenzo Cardinale; et al. "Cholangiocarcinoma 2020: the next horizon in mechanisms and management". Nature Reviews Gastroenterology & Hepatology 17 9 (2020): 557-588. https://doi.org/10.1038/s41575-020-0310-z.
    10.1038/s41575-020-0310-z
  36. Rodrigues, Pedro. "Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.". Journal of hepatology (2020): https://doi.org/10.1016/j.jhep.2020.09.010.
    10.1016/j.jhep.2020.09.010
  37. Rodrigues, Pedro. "TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.". Gut (2020): https://doi.org/10.1136/gutjnl-2019-319227.
    10.1136/gutjnl-2019-319227
  38. Rodrigues, Pedro. "Current and novel therapeutic opportunities for systemic therapy in biliary cancer.". British journal of cancer (2020): https://doi.org/10.1038/s41416-020-0987-3.
    10.1038/s41416-020-0987-3
  39. Rodrigues, Pedro. "Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial).". Cancers (2020): https://europepmc.org/articles/PMC7409102.
    10.3390/cancers12071900
  40. Rodrigues, Pedro. "Genomewide Association Study of Severe Covid-19 with Respiratory Failure.". The New England journal of medicine (2020): https://europepmc.org/articles/PMC7315890.
    10.1056/nejmoa2020283
  41. Rodrigues, Pedro. "Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets.". Liver international : official journal of the International Association for the Study of the Liver (2020): https://europepmc.org/articles/PMC7370945.
    10.1111/liv.14485
  42. Rodrigues, Pedro. "Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis.". Cells (2020): https://europepmc.org/articles/PMC7140677.
    10.3390/cells9030721
  43. Letizia Satriano; Monika Lewinska; Pedro M. Rodrigues; Jesus M. Banales; Jesper B. Andersen. "Metabolic rearrangements in primary liver cancers: cause and consequences". Nature Reviews Gastroenterology & Hepatology 16 12 (2019): 748-766. https://doi.org/10.1038/s41575-019-0217-8.
    10.1038/s41575-019-0217-8
  44. Patricia Munoz-Garrido; Pedro M. Rodrigues. "The jigsaw of dual hepatocellular–intrahepatic cholangiocarcinoma tumours". Nature Reviews Gastroenterology & Hepatology 16 11 (2019): 653-655. https://doi.org/10.1038/s41575-019-0185-z.
    10.1038/s41575-019-0185-z
  45. Rodrigues, Pedro. "Skeletal muscle miR-34a/SIRT1:AMPK axis is activated in experimental and human non-alcoholic steatohepatitis.". Journal of molecular medicine (Berlin, Germany) (2019): https://doi.org/10.1007/s00109-019-01796-8.
    10.1007/s00109-019-01796-8
  46. Rodrigues, Pedro. "CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells.". Biochimica et biophysica acta. Molecular basis of disease (2019): https://doi.org/10.1016/j.bbadis.2019.04.020.
    10.1016/j.bbadis.2019.04.020
  47. Rodrigues, Pedro. "Diagnostic and prognostic biomarkers in cholangiocarcinoma.". Liver international : official journal of the International Association for the Study of the Liver (2019): https://doi.org/10.1111/liv.14090.
    10.1111/liv.14090
  48. Pedro M. Rodrigues; Cecília M. P. Rodrigues; Rui E. Castro. "Modulation of liver steatosis by miR-21/PPARa". Cell Death Discovery 4 1 (2018): https://doi.org/10.1038/s41420-018-0076-z.
    10.1038/s41420-018-0076-z
  49. Rodrigues, Pedro. "Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?". Journal of hepatology (2018): https://doi.org/10.1016/j.jhep.2018.08.020.
    10.1016/j.jhep.2018.08.020
  50. Afonso, M.B.; Rodrigues, P.M.; Simão, A.L.; Gaspar, M.M.; Carvalho, T.; Borralho, P.; Bañales, J.M.; Castro, R.E.; Rodrigues, C.M.P.. "miRNA-21 ablation protects against liver injury and necroptosis in cholestasis". Cell Death and Differentiation (2017): 1-16. http://www.scopus.com/inward/record.url?eid=2-s2.0-85037678048&partnerID=MN8TOARS.
    10.1038/s41418-017-0019-x
  51. Rodrigues, P.M.; Afonso, M.B.; Simaõ, A.L.; Carvalho, C.C.; Trindade, A.; Duarte, A.; Borralho, P.M.; et al. "MiR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice". Cell Death and Disease 8 4 (2017): http://www.scopus.com/inward/record.url?eid=2-s2.0-85017474560&partnerID=MN8TOARS.
    10.1038/cddis.2017.172
  52. Rodrigues, Pedro. "Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma.". Journal of clinical medicine (2016): https://europepmc.org/articles/PMC4810101.
    10.3390/jcm5030030
  53. Afonso, M.B.; Rodrigues, P.M.; Simão, A.L.; Ofengeim, D.; Carvalho, T.; Amaral, J.D.; Gaspar, M.M.; et al. "Activation of necroptosis in human and experimental cholestasis". Cell Death and Disease 7 9 (2016): http://www.scopus.com/inward/record.url?eid=2-s2.0-85019011199&partnerID=MN8TOARS.
    10.1038/cddis.2016.280
  54. Afonso, M.B.; Rodrigues, P.M.; Carvalho, T.; Caridade, M.; Borralho, P.; Cortez-Pinto, H.; Castro, R.E.; Rodrigues, C.M.P.. "Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis". Clinical Science 129 8 (2015): 721-739. http://www.scopus.com/inward/record.url?eid=2-s2.0-84942872734&partnerID=MN8TOARS.
    10.1042/CS20140732
  55. Rodrigues, P.M.; Afonso, M.B.; Simaõ, A.L.; Borralho, P.M.; Rodrigues, C.M.P.; Castro, R.E.. "Inhibition of NF-¿ B by deoxycholic acid induces miR-21/PDCD4-dependent hepatocelular apoptosis". Scientific Reports 5 (2015): http://www.scopus.com/inward/record.url?eid=2-s2.0-84949257807&partnerID=MN8TOARS.
    10.1038/srep17528
  56. Ferreira, D.M.S.; Afonso, M.B.; Rodrigues, P.M.; Simão, A.L.; Pereira, D.M.; Borralho, P.M.; Rodrigues, C.M.P.; Castro, R.E.. "c-jun N-terminal kinase 1/c-jun activation of the p53/microRNA 34a/sirtuin 1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver". Molecular and Cellular Biology 34 6 (2014): 1100-1120. http://www.scopus.com/inward/record.url?eid=2-s2.0-84894244461&partnerID=MN8TOARS.
    10.1128/MCB.00420-13
  57. Pereira, D.M.; Rodrigues, P.M.; Borralho, P.M.; Rodrigues, C.M.P.. "Delivering the promise of miRNA cancer therapeutics". Drug Discovery Today 18 5-6 (2013): 282-289. http://www.scopus.com/inward/record.url?eid=2-s2.0-84874722125&partnerID=MN8TOARS.
    10.1016/j.drudis.2012.10.002
  58. Simões, A.E.S.; Pereira, D.M.; Amaral, J.D.; Nunes, A.F.; Gomes, S.E.; Rodrigues, P.M.; Lo, A.C.; et al. "Efficient recovery of proteins from multiple source samples after trizol®or trizol®LS RNA extraction and long-term storage". BMC Genomics 14 1 (2013): http://www.scopus.com/inward/record.url?eid=2-s2.0-84874944258&partnerID=MN8TOARS.
    10.1186/1471-2164-14-181
  59. Amaral, J.D.; Herrera, F.; Rodrigues, P.M.; Dionísio, P.A.; Outeiro, T.F.; Rodrigues, C.M.P.. "Live-cell imaging of p53 interactions using a novel Venus-based bimolecular fluorescence complementation system". Biochemical Pharmacology 85 6 (2013): 745-752. http://www.scopus.com/inward/record.url?eid=2-s2.0-84874114339&partnerID=MN8TOARS.
    10.1016/j.bcp.2012.12.009
Capítulo de livro
  1. Rodrigues, Pedro; Lapitz, A; Simão, A.L.; Perugorria, Maria J.; Arrese, Marco; Castro, Rui; Bañales, Jesus Maria. "Extracellular vesicles in non-alcoholic fatty liver disease: key players in disease pathogenesis and promising biomarker tools". In NAFLD and NASH Biomarkers in detection, diagnosis and monitoring, 157-180. Springer Nature, 2020.
    Publicado
  2. Rodrigues, Pedro; Olaizola, Paula; Paiva, Nuno A.; Perugorria, Maria J.; Bañales, Jesus Maria. "Intrahepatic Cholangiocarcinoma: the emerging entity". In Therapy in Liver Diseases, 293-310. Licitelco España, 2019.
    Publicado
Poster em conferência
  1. Rodrigues, Pedro; Afonso MB, Simao AL, Islam T, Gaspar MM, O’Rourke CJ, Lewinska M, Andersen JB, Arretxe E, Alonso C, Santos-Laso A; Jimenez-Aguero R, Eizaguirre E, Bujanda L, Pareja MJ, Prip-Buus C, Banales JM, Rodrigues CMP, Castro RE. "hsa-miR-21-5p disturbs the metabolic network in patients with NAFLD and is increased in NASH-associated HCC, contributing to hepatocarcinogenesis". Trabalho apresentado em The Digital Liver Cancer Summit, 2021.
  2. Tomas AF, Simao AL, Munoz-Bellvis L, Lapitz A, Bujanda L; Rodrigues, Pedro; Banales JM, Marin JJG, Rodrigues CMP, Macias RIR, Castro RE. "Serum miRNA profiling for the differential diagnosis of distal cholangiocarcinoma from pancreatic diseases". Trabalho apresentado em The Digital Liver Cancer Summit, 2021.
  3. Ruiz de Gauna M, Biancaniello F; Rodrigues, Pedro; Gonzalez-Romero F, Labiano I, Aurrekoetxea I, Lapitz A, Nieva-Zuluaga A, Benito-Vicente A, Apodaka-Biguri M, Perugorria; Saénz de Urturi D, Gomez-Santos B, Carr-Ugarte H, Buque X, Delgado I, Bujanda L, Martin CA, Banales JM, Aspichueta P; Ruiz de Gauna, Mikel; Biancaniello, Francesca; González-Romero, Francisco; et al. "Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids". Trabalho apresentado em The Digital Liver Cancer Summit, 2021.
    10.1002/hep.32344
  4. Ruiz de Gauna, M; Rodrigues, Pedro; Gonzalez-Romero F, Labiano I, Aurrekoetxea I, Biancaniello F, Nieva-Zuluaga A, Lapitz A, Apodaka-Biguri M; Perugorria MJ, Saenz de Urturi D, Gomez-Santos B, Buqué X, Delgado I, Bujanda L, Calvisi DF, Banales JM, Aspichueta P. "Deciphering the rewiring of lipid metabolism in cholangiocarcinoma: novel therapeutic opportunities". Trabalho apresentado em Cholangiocarcinoma Foundation Annual Meeting, 2020.
  5. Lapitz A, Azkargorta M, O’Rourke CJ, Arbelaiz A, La Casta A, Vesterhus M, Milkiewicz P, Jimenez-Agüero R, Riaño I; Landa A, Ibarra C, Bustamante J, Perugorria MJ, Bujanda L, Falcon-Perez JM; Rodrigues, Pedro; Andersen JB, Elortza F, Folseraas T, Karlsen TH, Banales JM. "Novel protein biomarkers in serum extracellular vesicles for the diagnosis of cholangiocarcinoma (CCA) in patients with primary sclerosing cholangitis (PSC)". Trabalho apresentado em Cholangiocarcinoma Foundation Annual Meeting, 2020.
  6. Lapitz, A; Rodrigues, Pedro; Arbelaiz A, Lavin JL, O’Rourke CJ, Krawczyk M, Santos-Laso A, Perugorria MJ, La Casta A, Jimenez-Agüero R, Ibarra C; Sanchez-Campos A, Jimeno JP, Riaño I, Gonzalez E, Lammert F, Marzioni M, Macias RIR, Marin JJG, Karlsen TH, Bujanda L; Falcon-Perez JM, Andersen JB, Aransay AM, Banales JM; Arbelaiz A, Lavin JL, O¿Rourke CJ, Krawczyk M, Santos-Laso A, Perugorria MJ, La Casta A, Jimenez-Agüero R; Ibarra C, Sanchez-Campos A, Jimeno JP, Riaño I, Gonzalez E, Lammert F, Marzioni M, Macias RIR, Marin JJG, Karlsen TH; Bujanda L, Falcon-Perez JM, Andersen JB, Aransay AM, Banales JM. "Serum and urine extracellular vesicles contain specific RNAs with diagnostic capacity for cholangiocarcinoma, being possibly involved in disease pathogenesis". Trabalho apresentado em Cholangiocarcinoma Foundation Annual Meeting, 2020.
  7. Rodrigues, Pedro; Afonso MB, Simão AL, Islam T, Gaspar MM, O’Rourke CJ, Andersen JB, Santos-Laso A, Jimenez-Agüero R, Eizaguirre E; Bujanda L, Pareja MJ, Prip-Buus C, Banales JM, Rodrigues CMP, Castro RE. "miR-21 is increased in patients with NASH-associated HCC and contributes to hepatocarcinogenesis in mice with NAFLD". Trabalho apresentado em 55th The Digital International Liver Congress, 2020.
  8. Lapitz A, Azkargorta M, O’Rourke CJ, Arbelaiz A, La Casta A, Vesterhus M, Milkiewicz P, Jimenez-Agüero R, Riaño I; Landa A, Ibarra C, Bustamante J, Perugorria MJ, Bujanda L, Falcon-Perez JM; Rodrigues, Pedro; Andersen JB, Elortza F, Folseraas T, Karlsen TH, Banales JM. "Novel protein biomarkers in serum extracellular vesicles for the diagnosis of cholangiocarcinoma (CCA) in patients with primary sclerosing cholangitis (PSC)". Trabalho apresentado em 55th The Digital International Liver Congress, 2020.
  9. Santos-Laso A, Izquierdo-Sánchez I; Rodrigues, Pedro; Huang BQ, Azkargorta M, Lapitz A, Munoz-Garrido P, Arbelaiz A, Caballero FJ, Fernandez-Barrena MG, Jimenez-Agüero R; Argemi J, Aragon T, Elortza F, Marzioni M, Drenth JPH, LaRusso NF, Bujanda L, Perugorria MJ, Banales JM. "Proteostasis improvement in cystic cholangiocytes alleviates endoplasmic reticulum stress and halts polycystic liver disease". Trabalho apresentado em 55th The Digital International Liver Congress, 2020.
  10. Afonso MB, Simão AL; Rodrigues, Pedro; Mateus-Pinheiro M, Gaspar MM, Majdi A, Ratziu V, Bañales JM, Gautheron J, Castro RE, Rodrigues CMP. "Hepatic RIP3 signalling differentially modulates lipid metabolism and inflammation/carcinogenesis in non-alcoholic steatohepatitis". Trabalho apresentado em 55th The Digital International Liver Congress, 2020.
  11. Islam, T; Rodrigues, Pedro; Ignacakova H, Afonso MB, Simão AL, Rodrigues CMP, Castro RE. "Composite targeting of nuclear receptors protects mice from NAFLD progression towards HCC". Trabalho apresentado em 55th The Digital International Liver Congress, 2020.
  12. Santos-Laso A, Velaz A, Alonso C, Eizaguirre E, Martínez-Arranz I, Jímenez-Agüero R, Pareja MJ, Izquierdo-Sanchez; Riaño I, Andersen JB, Arretxe E, Mincholé I, Ortiz P, Perugorria MJ, Landa A, Krawczyk M, Lammert F, Castro RE; Aspichueta P, Romero-Gomez M, Bujanda L; Rodrigues, Pedro; Banales, Jesus Maria. "Obese patients carrying NAFLD-associated genetic variants present specific serum and liver lipidomic profiles: identification of a lipidomic signature in serum to estimate the liver fat content". Trabalho apresentado em XLV Congreso Anual de la Asociación Española para el Estudio del Hígado, 2020.
  13. Labiano I, Esparza-Baquer A, Agirre-Lizaso A, Oakley F; Rodrigues, Pedro; Sharif O, Hijona E, Jimenez-Agüero R, Milkiewicz P, Milkiewica M, Rodriguez-Romero F, Aspichueta P, Monte MJ, Marin JJG; Vucur M, Luedde T, Marzioni M, Mann DA, Bujanda L, Banales JM, Perugorria MJ. "El receptor anti-inflamatorio TREM2 protege al hígado frente al daño inducido por colestasis". Trabalho apresentado em XLV Congreso Anual de la Asociación Española para el Estudio del Hígado (AEEH), 2020.
  14. Lapitz A, Azkargorta M, O’Rourke CJ, Arbelaiz A, La Casta A, Vesterhus M, Milkiewicz P, Jimenez-Agüero R, Riaño I; Landa A, Ibarra C, Bustamante J, Perugorria MJ, Bujanda L, Falcon-Perez JM; Rodrigues, Pedro; Andersen JB, Elortza F, Folseraas T, Karlsen TH, Banales JM. "Nuevos biomarcadores proteicos en vesículas extracelulares de suero para el diagnóstico del colangiocarcinoma (CCA) en pacientes con colangitis esclerosante primaria (PSC)". Trabalho apresentado em XLV Congreso Anual de la Asociación Española para el Estudio del Hígado, 2020.
  15. Afonso MB, Simão AL; Rodrigues, Pedro; Mateus-Pinheiro M, Gaspar MM, Majdi A, Ratziu V, Banales JM, Gautheron J, Castro RE, Rodrigues CMP. "Hepatic RIP3 signalling differentially modulates lipid metabolism and inflammation/carcinogenesis in non-alcoholic steatohepatitis". Trabalho apresentado em Liver Cancer Summit 2020, 2020.
  16. Rodrigues, Pedro; Afonso MB, Simão AL, Islam T, Gaspar MM, O’Rourke CJ, Andersen JB, Santos-Laso A, Jimenez-Agüero R, Eizaguirre E; Bujanda L, Pareja MJ, Prip-Buus C, Banales JM, Rodrigues CMP, Castro RE. "miR-21 is increased in patients with NASH-associated HCC and contributes to hepatocarcinogenesis in mice with NAFLD". Trabalho apresentado em EASL Liver Cancer Summit, 2020.
  17. Simao, André Lopes; Rodrigues, Pedro; Afonso MB, O’Rourke CJ, Andersen JB, Santos-Laso A, Jimenez-Agüero R, Eizaguirre E, Bujanda L; Pareja MJ, Macias RIR, Banales JM, Rodrigues CMP, Castro RE. "miR-34a is activated in NAFLD and NASH-associated HCC, and correlates with key disease hallmarks". Trabalho apresentado em Liver Cancer Summit 2020, 2020.
  18. Lapitz A, Azkargorta M, O’Rourke CJ, Arbelaiz A, La Casta A, Vesterhus M, Milkiewicz P, Jimenez-Agüero R, Riaño I; Landa A, Ibarra C, Bustamante J, Perugorria MJ, Bujanda L, Falcon-Perez JM; Rodrigues, Pedro; Andersen JB, Elortza F, Folseraas T, Karlsen TH, Banales JM. "Novel protein biomarkers in serum extracellular vesicles for the diagnosis of cholangiocarcinoma (CCA) in patients with primary sclerosing cholangitis (PSC)". Trabalho apresentado em Liver Cancer Summit 2020, 2020.
  19. Labiano I, Esparza-Baquer A, Sharif O, Agirre-Lizaso A, Oakley F; Rodrigues, Pedro; Hijona E, Jimenez-Agüero R, Landa A, La Casta A, Zaki MYW, O'Rourke CJ, Munoz-Garrido P, Azkargorta M, Elortza F; Schabbauer G, Andersen JB, Knapp S, Mann DA, Bujanda L, Banales JM, Perugorria MJ. "TREM2 protects the liver against hepatocellular carcinoma through multifactorial protective mechanisms". Trabalho apresentado em EASL Liver Cancer Summit, 2020.
  20. Islam, T; Rodrigues, Pedro; Ignacakova H, Afonso MB, Simão AL, Rodrigues CMP, Castro RE. "Composite targeting of nuclear receptors protects mice from NAFLD progression towards HCC". Trabalho apresentado em EASL Liver Cancer Summit, 2020.
  21. Labiano I, Esparza-Baquer A, Sharif O, Agirre-Lizaso A, Oakley F; Rodrigues, Pedro; Hijona E, Jimenez-Agüero R, Landa A, La Casta A, Zaki MYW, O'Rourke CJ, Munoz-Garrido P, Azkargorta M, Elortza F; Schabbauer G, Andersen JB, Knapp S, Mann DA, Bujanda L, Banales JM, Perugorria MJ. "TREM2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms". Trabalho apresentado em The International Liver Cancer Association Virtual Congress 2020, 2020.
  22. Islam T, Simão AL, Afonso MB; Rodrigues, Pedro; Gama-Carvalho M, Rodrigues CMP, Castro RE. "Identification of novel miRNAs associated with experimental NAFLD pathogenesis". Trabalho apresentado em 27th United European Gastroenterology Week, 2019.
  23. Simao AL; Rodrigues, Pedro; Afonso MB, Santos-Laso A, Jimenez-Agüero R, Eizaguirre E, Bujanda L, Pareja MJ, Banales JM, Rodrigues CMP, Castro RE. "Liver microRNA-34a is activated in multiple animal models of NAFLD and correlates with key disease hallmarks in human patients". Trabalho apresentado em 27th United European Gastroenterology Week, 2019.
  24. Santos-Laso A, Velaz A, Alonso C, Eizaguirre E, Martínez-Arranz I, Jímenez-Agüero R, Pareja MJ, Izquierdo-Sanchez, L; Riaño I, Andersen JB, Arretxe E, Mincholé I, Ortiz P, Perugorria MJ, Landa A, Krawczyk M, Lammert F, Castro RE; Aspichueta P, Romero-Gomez M, Bujanda L; Rodrigues, Pedro; Banales, JM. "Obese patients carrying NAFLD-associated genetic variants present specific serum and liver lipidomic profiles: identification of a lipidomic signature in serum to estimate the liver fat content". Trabalho apresentado em 3rd EASL NAFLD Summit, 2019.
  25. Islam, T; Rodrigues, Pedro; Afonso MB, Simão AL, Rodrigues CMP, Castro RE. "Triple targeting of nuclear receptors protects against diet-induced NAFLD in mice". Trabalho apresentado em 3rd EASL NAFLD Summit, 2019.
  26. Simao, AL; Rodrigues, Pedro; Afonso MB, Santos-Laso A, Jiménez-Agüero R, Eizaguirre E, Bujanda L, Pareja MJ, Banales JM, Rodrigues CMP, Castro RE. "miR-34a is strongly activated in human and experimental NAFLD, correlating with key disease hallmarks". Trabalho apresentado em 3rd EASL NAFLD Summit, 2019.
  27. Afonso, MB; Rodrigues, Pedro; Simão AL, Pinheiro MM, Gaspar MM, Castro RE, Rodrigues CMP. "RIP3-dependent signalling impacts on lipid metabolism and halts disease progression in experimental models of non-alcoholic fatty liver disease". Trabalho apresentado em 3rd EASL NAFLD Summit, 2019.
  28. Esparza-Baquer A, Labiano I, Sharif O, Oakley F; Rodrigues, Pedro; Hijona E, Jiménez-Agüero R, Lacasta A, Zaki MY, O'Rourke CJ, Munoz-Garrido P, Andersen JB, Knapp S, Mann DA. "Non-parenchymal TREM-2 halts hepatocarcinogenesis through the inhibition of liver inflammation and hepatocyte proliferation". Trabalho apresentado em 54th The International Liver Congress, 2019.
  29. Esparza-Baquer A, Labiano I, Sharif O, Oakley F; Rodrigues, Pedro; Hijona E, Jiménez-Agüero R, Lacasta A, Zaki MY, O'Rourke CJ, Munoz-Garrido P, Andersen JB, Knapp S, Mann DA; Bujanda L, Banales JM, Perugorria MJ. "Non-parenchymal TREM-2 halts hepatocarcinogenesis through the inhibition of liver inflammation and hepatocyte proliferation". Trabalho apresentado em 3rd EASL HCC Summit, 2019.
  30. Afonso, MB; Rodrigues, Pedro; Simao AL, Gaspar MM, Castro RE, Rodrigues CMP. "RIP3-dependent signalling exerts divergent effects on liver steatosis and carcinogenesis in experimental non-alcoholic fatty liver disease". Trabalho apresentado em 3rd EASL HCC Summit, 2019.
  31. Rodrigues, Pedro; Afonso MB, Simão AL, Gaspar MM, Rodrigues CMP, Castro RE. "miR-21/PPARalpha activation in NASH promotes progression towards hepatocellular carcinoma". Trabalho apresentado em 3rd EASL HCC Summit, 2019.
  32. Islam, T; Afonso MB, Lenoir V; Rodrigues, Pedro; Castro RE, Prip-Buus C, Rodrigues CMP. "Restoration of Mitochondrial Respiratory Chain Activity by RIP3 Depletion in Experimental NAFLD". Trabalho apresentado em 2nd EASL NAFLD Summit, 2018.
  33. Santos AA, Afonso MB; Rodrigues, Pedro; Castro RE, Rodrigues CMP. "miR-21 contributes to the onset and progression of liver disease through the deregulation of small intestine permeability". Trabalho apresentado em EASL Monothematic Conference: Gut-Liver Axis, 2018.
  34. Simao AL, Afonso MB; Rodrigues, Pedro; Amaral AJ, Gama-Carvalho M, Zorzano A, Rodrigues CMP, Castro RE. "Role of mitofusin-2 in NAFLD and targeting by miRNAs". Trabalho apresentado em 53rd The International Liver Congress, 2018.
  35. Rodrigues, Pedro; Afonso MB, Simão AL, Gaspar MM, Rodrigues CMP, Castro RE. "miR-21 ablation prevents NASH-associated hepatocellular carcinoma". Trabalho apresentado em 2nd EASL HCC Summit, 2018.
  36. Afonso MB; Rodrigues, Pedro; Simao AL, Gaspar MM, Castro RE, Rodrigues CMP. "RIP3-dependent signalling contributes to non-alcoholic fatty liver disease-related carcinogenesis". Trabalho apresentado em 2nd EASL HCC Summit, 2018.
  37. Afonso, MB; Rodrigues, Pedro; Simão AL, Gaspar MM, Carvalho T, Borralho P, Banales JM, Castro RE, Rodrigues CMP. "miRNA-21 is overexpressed in primary biliary cholangitis and mediates liver injury and necroptosis in experimental cholestasis". Trabalho apresentado em 25th United European Gastroenterology Week, 2017.
  38. Simão AL, Afonso MB; Rodrigues, Pedro; Amaral AJ, Gama-Carvalho M, Zorzano A, Rodrigues CMP, Castro RE. "Modulation of mitochondrial dynamics by miRNAs in NAFLD". Trabalho apresentado em 25th United European Gastroenterology Week, 2017.
  39. Simão AL, Afonso MB; Rodrigues, Pedro; Amaral AJ, Gama-Carvalho M, Zorzano A, Rodrigues CMP, Castro RE. "Altered small intestine microbiota toward family Lactobacillaceae in miR-21 KO mice". Trabalho apresentado em 25th United European Gastroenterology Week, 2017.
  40. Rodrigues, Pedro; Afonso MB, Simão AL, Gaspar MM, Rodrigues CMP, Castro RE. "miR-21 ablation prevents NASH-associated hepatocellular carcinoma". Trabalho apresentado em 1st EASL NAFLD Summit, 2017.
  41. Afonso, MB; Rodrigues, Pedro; Simao AL, Gaspar MM, Castro RE, Rodrigues CMP. "RIP3-dependent signalling contributes to non-alcoholic fatty liver disease-related carcinogenesis". Trabalho apresentado em 1st EASL NAFLD Summit, 2017.
  42. Simão AL, Afonso MB; Rodrigues, Pedro; Amaral AJ, Gama-Carvalho M, Zorzano A, Rodrigues CMP, Castro RE. "Role of mitofusin-2 in NAFLD and targeting by miRNAs". Trabalho apresentado em 1st EASL NAFLD Summit, 2017.
  43. Afonso, MB; Rodrigues, Pedro; Simao AL, Gaspar MM, Castro RE, Rodrigues CMP. "microRNA-21 is overexpressed in primary biliary cholangitis and contributes to liver injury and necroptosis in cholestatic bile duct-ligated mice". Trabalho apresentado em EASL Monothematic Conference - Cholangiocytes in health and disease: from basic science to novel treatments, 2017.
  44. Rodrigues, Pedro; Afonso MB, Simão AL, Catarina CC, Trindade A, Duarte A, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CMP, Castro R. "miR-21 ablation and obeticholic acid ameliorates NASH in mice". Trabalho apresentado em 52nd The International Liver Congress, 2017.
  45. Afonso, MB; Rodrigues, Pedro; Simao AL, Gaspar MM, Castro RE, Rodrigues CMP. "miRNA-21-deficiency reduces liver injury, fibrosis and necroptosis in cholestatic bile duct-ligated mice". Trabalho apresentado em 52nd The International Liver Congress, 2017.
  46. Simão AL, Afonso MB; Rodrigues, Pedro; Amaral AJ, Gama-Carvalho M, Cortez-Pinto H, Rodrigues CMP, Castro RE. "Activation of miR-34a contributes to liver and muscle insulin resistance in experimental and human Non-Alcoholic Fatty Liver Disease". Trabalho apresentado em 52nd The International Liver Congress, 2017.
  47. Rodrigues, Pedro; Afonso MB, Simao AL, Caridade M, Carvalho CC, Trindade A, Duarte A, Borralho PM, Machado MV, Cortez-Pinto H; Rodrigues CMP, Castro RE. "miR-21 ablation and obeticholic acid ameliorate non-alcoholic steatohepatitis in mice". Trabalho apresentado em Keystone symposia: Bile Acid Receptors as Signal Integrators in Liver and Metabolism, 2017.
  48. Rodrigues, Pedro; Afonso MB, Simão AL, Catarina CC, Trindade A, Duarte A, Borralho PM, Machado MV, Cortez-Pinto H; Rodrigues CMP, Castro RE. "miR-21 ablation and obeticholic acid ameliorates NASH in mice". Trabalho apresentado em 1st EASL HCC Summit 2017, 2017.
  49. Santos AA, Afonso MB; Rodrigues, Pedro; Castro RE, Rodrigues CMP. "miRNA-21 deficiency decreases small intestine permeability after bile duct ligation in mice". Trabalho apresentado em 1st EASL HCC Summit 2017, 2017.
  50. Afonso, MB; Rodrigues, Pedro; Simão AL, Gaspar MM, Castro RE, Rodrigues CMP. "miRNA-21-deficiency reduces liver injury, fibrosis and necroptosis in cholestatic bile duct-ligated mice". Trabalho apresentado em 1st EASL HCC Summit 2017, 2017.
  51. Simão AL, Afonso MB; Rodrigues, Pedro; Amaral AJ, Gama-Carvalho M, Cortez-Pinto H, Rodrigues CMP, Castro RE. "Activation of miR-34a contributes to liver and muscle insulin resistance in experimental and human Non-Alcoholic Fatty Liver Disease". Trabalho apresentado em 1st EASL HCC Summit 2017, 2017.
  52. Rodrigues, Pedro. "Liver and skeletal muscle miR-34a contributes to mitochondrial dysfunction and insulin resistance in experimental NAFLD". Trabalho apresentado em 24th United European Gastroenterology Week, 2016.
  53. Rodrigues, Pedro; Afonso MB, Simão AL, Caridade M, Carvalho CC, Trindade A, Duarte A, Borralho PM, Machado M, Cortez-Pinto H; Rodrigues CMP, Castro RE. "Dual targeting of nuclear receptors ameliorates NAFLD pathogenesis in different dietary murine models". Trabalho apresentado em XXIV International Bile Acid Meeting: Bile Acids in Health and Disease, 2016.
  54. Rodrigues, Pedro; Simão AL, Cortez-Pinto H, Ofengeim D, Amaral JD, Castro RE, Yuan J, Rodrigues CMP. "The role of necroptosis in acute and chronic cholestasis". Trabalho apresentado em XXIV International Bile Acid Meeting: Bile Acids in Health and Disease, 2016.
  55. Rodrigues, Pedro; Afonso MB, Simão AL, Caridade M, Carvalho CC, Trindade A, Duarte A, Borralho PM, Machado M, Cortez-Pinto H; Rodrigues CMP, Castro RE. "Inhibition of miR-21 prevents development of fibrosis and ameliorates NAFLD pathogenesis in mice". Trabalho apresentado em EASL Monothematic Conference: Liver fibrosis – the next goal of targeted therapy?, 2016.
  56. Rodrigues, Pedro; Afonso, MB; Simão AL, Cortez-Pinto H, Ofengeim D, Amaral JD, Castro RE, Yuan J, Rodrigues CMP. "The role of necroptosis in chronic cholestasis-induced fibrosis". Trabalho apresentado em EASL Monothematic Conference: Liver fibrosis: - the next goal of targeted therapy?, 2016.
  57. Afonso, MB; Rodrigues, Pedro; Simão AL, Cortez-Pinto H, Ofengeim D, Amaral JD, Castro RE, Yuan J, Rodrigues CMP. "RIP3 regulates acute cholestasis-associated necroptotic signaling and cell death". Trabalho apresentado em 51st International Liver Congress, 2016.
  58. Rodrigues, Pedro; Afonso MB, Simão AL, Caridade M, Carvalho CC, Trindade A, Duarte A, Borralho PM, Machado M, Cortez-Pinto H; Rodrigues CMP, Castro RE. "miR-21 inhibition and obeticholic acid ameliorate non-alcoholic steatohepatitis in dietary animal models". Trabalho apresentado em 51st International Liver Congress, EASL, Barcelona, Spain, 2016, 2016.
  59. Rodrigues, Pedro; Afonso MB, Simão AL, Caridade M, Carvalho CC, Trindade A, Duarte A, Borralho PM, Machado M, Cortez-Pinto H; Rodrigues CMP, Castro RE. "Dual targeting of nuclear receptors ameliorates NAFLD pathogenesis in mice". Trabalho apresentado em 66th Annual Meeting of the American Association for the Study of Liver Diseases, 2015.
  60. Afonso, MB; Rodrigues, Pedro; Simão AL, Cortez-Pinto H, Ofengeim D, Amaral JD, Castro RE, Yuan J, Rodrigues CMP. "RIP3-dependent signalling contributes to necroinflammation in cholestatic liver injury". Trabalho apresentado em 66th Annual Meeting of the American Association for the Study of Liver Diseases, 2015.
  61. Afonso, MB; Rodrigues, Pedro. "RIP3-dependent hepatocyte necroptosis in human and experimental non-alcoholic steatohepatiti". Trabalho apresentado em 66th Annual Meeting of the American Association for the Study of Liver Diseases, 2015.
  62. Simão AL, Afonso MB; Rodrigues, Pedro; Amaral AJ, Carvalho M, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CMP, Castro RE. "miRNA-339-3p is increased in human and experimental models of NAFLD and targetedby TUDCA in insulin-resistant muscle cells". Trabalho apresentado em 66th Annual Meeting of the American Association for the Study of Liver Diseases, 2015.
  63. Afonso, MB; Rodrigues, Pedro; Simão AL, Cortez-Pinto H, Ofengeim D, Amaral JD, Castro RE, Yuan J, Rodrigues CMP. "RIP3 kinase contributes to necroinflammation in the cholestatic liver". Trabalho apresentado em 23rd United European Gastroenterology Week, 2015.
  64. Afonso, MB; Rodrigues, Pedro; Simão AL, Cortez-Pinto H, Ofengeim D, Amaral JD, Castro RE, Yuan J, Rodrigues CMP. "Necroptosis contributes to the pathogenesis of cholestatic liver injury". Trabalho apresentado em 50th International Liver Congress, 2015.
  65. Rodrigues, Pedro; Afonso MB, Simão AL, Caridade M, Carvalho CC, Trindade A, Duarte A, Borralho PM, Machado M, Cortez-Pinto H; Rodrigues CMP, Castro RE. "MiR-21 inhibition and FXR activation synergistically ameliorate disease pathogenesis in a mouse model of NAFLD". Trabalho apresentado em 50th International Liver Congress, 2015.
  66. Simão AL, Afonso MB; Rodrigues, Pedro; Amaral AJ, Gama-Carvalho M, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CMP, Castro RE. "Modulation of muscle microRNA expression profiles in patients with NAFLD and in C2C12 cells incubated with palmitic acid". Trabalho apresentado em 50th International Liver Congress, 2015.
  67. Rodrigues, Pedro; Afonso MB, Simão AL, Caridade M, Carvalho CC, Trindade A, Duarte A, Borralho PM, Machado M, Cortez-Pinto H; Rodrigues CMP, Castro RE. "MiR-21 inhibition and FXR activation synergistically ameliorate disease pathogenesis in a mouse model of NAFLD". Trabalho apresentado em EASL Monothematic Conference: Microbiota, Metabolism and NAFLD, 2015.
  68. Simão AL, Afonso MB; Rodrigues, Pedro; Amaral AJ, Gama-Carvalho M, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CMP, Castro RE. "Modulation of muscle micrRNA expression profiles in patients with NAFLD and in C2C12 cells incubated with palmitic acid". Trabalho apresentado em EASL Monothematic Conference: Microbiota, Metabolism and NAFLD, 2015.
  69. Afonso, MB; Rodrigues, Pedro; Simão AL, Cortez-Pinto H, Ofengeim D, Amaral JD, Castro RE, Yuan J, Rodrigues CMP. "The dual role of necroptosis in cholestasis". Trabalho apresentado em 23rd Conference of the European Cell Death Organization-Death pathways and beyond, 2015.
  70. Rodrigues, Pedro; Afonso MB, Simão AL, Ferreira DMS, Borralho PM, Rodrigues CMP, Castro RE. "Deoxycholic acid triggers primary rat hepatocyte apoptosis in a dose-dependent manner by hampering Caspase-2/NF-kB-associated activation of miRNA-21". Trabalho apresentado em 64th Annual Meeting of the American Association for the Study of Liver Diseases, 2014.
  71. Rodrigues, Pedro; Afonso MB, Simão AL, Ferreira DMS, Borralho PM, Rodrigues CMP, Castro RE. "Modulation of NF-kB activity by DCA: Effects on miR-21, apoptosis and inflammation". Trabalho apresentado em 49th International Liver Congress, 2014.
  72. Afonso MB, Caridade M; Rodrigues, Pedro; Cortez-Pinto H, Amaral JD, Castro RE, Rodrigues CMP. "Regulated necrosis in Bile acid-induced toxicity". Trabalho apresentado em XXIII International Bile Acid Meeting: Bile Acids as Signal Integrators and Metabolic Modulators, 2014.
  73. Rodrigues, Pedro; Afonso MB, Simão AL, Borralho PM, Rodrigues CMP, Castro RE. "Deoxycholic acid-induced oxidative stress and NF-¿B inhibition contributes for apoptosis of primary rat hepatocytes via miR-21/PDCD4". Trabalho apresentado em XXIII International Bile Acid Meeting: Bile Acids as Signal Integrators and Metabolic Modulators, 2014.
  74. Afonso, MB; Rodrigues, Pedro; Caridade M, Cortez-Pinto H, Castro RE, Rodrigues CMP. "A necroptose contribui para a patogénese da doença hepática crónica". Trabalho apresentado em Semana Digestiva 2014, 2014.
  75. Ferreira DMS, Afonso MB; Rodrigues, Pedro; Borralho PM, Rodrigues CMP, Castro RE. "Jnk1/p53/miR-34a/SIRT1 as a key pathway mediating deoxycholic acid-induced apoptosis in primary rat hepatocytes". Trabalho apresentado em 64th Annual Meeting of the American Association for the Study of Liver Diseases, 2013.
  76. Rodrigues, Pedro; Afonso MB, Simão AL, Ferreira DMS, Borralho PM, Rodrigues CMP, Castro RE. "Deoxycholic Acid Inhibits NF-¿B-mediated Activation of miR-21 in Primary Rat Hepatocytes in a Dose-dependent Manner". Trabalho apresentado em 21st United European Gastroenterology Week, 2013.
  77. Ferreira DMS, Afonso MB; Rodrigues, Pedro; Borralho PM, Rodrigues CMP, Castro RE. "Deoxycholic acid induces apoptosis in primary rat hepatocytes via JNK1/p53/miR-34a/SIRT1". Trabalho apresentado em 21st United European Gastroenterology Week, 2013.
  78. Rodrigues, Pedro; Afonso MB, Simão AL, Ferreira DMS, Borralho PM, Rodrigues CMP, Castro RE. "Modulação do NF-kB e da via miR-21/PDCD4 Na apoptose de hepatócitos primários de rato induzida pelo ácido desoxicólico". Trabalho apresentado em XXXVIII Congresso Nacional de Gastroenterologia, Endoscopia Digestiva e Hepatologia, 2013.
  79. Ferreira DMS, Afonso MB; Rodrigues, Pedro; Borralho PM, Rodrigues CMP, Castro RE. "Ativação de miR-34a e JNK na apoptose de hepatócitos primaries de rato induzida por ácidos biliares tóxicos". Trabalho apresentado em XXXVIII Congresso Nacional de Gastroenterologia, Endoscopia Digestiva e Hepatologia, 2013.
  80. Rodrigues, Pedro; Afonso MB, Simão AL, Ferreira DMS, Borralho PM, Rodrigues CMP, Castro RE. "Dose-dependent modulation of NF-kB and miR-21 by deoxycholic acid during apoptosis of primary rat hepatocytes". Trabalho apresentado em 48th International Liver Congress, 2013.
  81. Ferreira DMS, Borralho PM, Afonso MB; Rodrigues, Pedro; Machado MV, Cortez-Pinto H, Rodrigues CMP, Castro RE. "Ursodeoxycholic acid inhibits activation of miR-34a/SIRT1/p53, a pro-apoptotic pathway associated with disease severity in non-alcoholic fatty liver". Trabalho apresentado em XXII International Bile Acid Meeting Hepatic and Extrahepatic Targets of Bile Acid Signaling, 2013.
  82. Ferreira DMS, Afonso MB; Rodrigues, Pedro; Borralho PM, Rodrigues CMP, Castro RE. "miR-34a regulation of SIRT1 and p53 in primary rat hepatocytes exposed to deoxycholic acid.". Trabalho apresentado em 63rd Annual Meeting of the American Association for the Study of Liver Diseases, 2012.
  83. Castro RE, Afonso MB, Ferreira DMS; Rodrigues, Pedro; Borralho PM, Rodrigues CMP. "The miRNA-21/PDCD4 cell death/survival axis in the response of rat hepatocytes to bile acids". Trabalho apresentado em 20th United European Gastroenterology Week, 2012.
  84. Castro RE, Afonso MB, Ferreira DMS; Rodrigues, Pedro; Borralho PM, Rodrigues CMP. "The miR-21/PDCD4 pathway in the response of rat hepatocytes to bile acids: deciding between cell death and survival". Trabalho apresentado em XXII International Bile Acid Meeting Hepatic and Extrahepatic Targets of Bile Acid Signaling, 2012.
  85. Ferreira DMS, Afonso MB; Rodrigues, Pedro; Borralho PM, Rodrigues CMP, Castro RE. "Hepatocyte cell death by deoxycholic acid is mediated by miR-34a regulation of SIRT1 and p53 proteins". Trabalho apresentado em 20th Euroconference on Apoptosis “From Death to Eternity”, 2012.
  86. Rodrigues, Pedro; Amaral JD, Garrudo FF, Herrera F, Outeiro TF, Rodrigues CMP. "Development of a drug screening platform of p53/Mdm-2 protein-protein interaction". Trabalho apresentado em 37th Jornadas Portuguesas de Genética,, 2012.
  87. Pinho J, Wilton J, Nobre L; Rodrigues, Pedro; Paes de Sousa PM, Pauleta SR. "Factors involved in the formation of electron transfer complexes: a novel copper sensor protein". Trabalho apresentado em Ciência 2010 – Encontro com a Ciência e Tecnologia, 2010.

Propriedade Intelectual

Patente
  1. Olaizola, Irene; Olaizola, Paula; Rodrigues, Pedro; Caballero-Camino, Francisco Javier; Bañales, Jesus Maria; Mikel Odriozola; Ivan Rivilla; et al. 2023. "Heterociclos metalados polielectrofílicos derivados de 2-(piridin-2-il)imidazo[1,2-a]piridina y su uso como agentes quimioterápicos". Espanha.
    Pendente
Atividades

Apresentação oral de trabalho

Título da apresentação Nome do evento
Anfitrião (Local do evento)
2023/06/24 Emerging biomarkers for surveillance of biliary tract cancer in AILD International Liver Conference
EASL (Vienna, Áustria)
2023/06/09 Lipotoxicity-driven metabolic associated fatty liver disease Monothematic conference on Lipidomics, lipotoxicity and organic damage: uncovering new lipid dependent pathophysiology pathways, biomarkers and therapy targets
EAS (Prague, República Checa)
2023/06/01 Experimental models for the study of cholangiocarcinoma: pros and cons Drug Discovery and Chemoresistance in CCA” Euro-CholangioNet COST Action Training School
COST (Patras, Grécia)
2023/06/01 Serum Proteome for the Discovery of Biomarkers AASLD Symposium on Multi-omics Approaches for Cholestatic Liver Diseases
AASLD (Virtual, Estados Unidos)
2023/05/12 KLF5 upregulation is a common event in cholangiocarcinoma, acting as an oncogene and constituting a bad prognostic factor AMMF 2023 European Cholangiocarcinoma Conference
AMMF (London, Reino Unido)
2023/04/13 Beyond ctDNA: is there a role for liquid biopsy in early diagnosis? Cholangiocarcinoma Foundation 2023 Annual Conference
CCF (Salt Lake City, Estados Unidos)
2023/03/16 miRNAs in liver pathophysiology: small molecules with big functional impact 48 Annual Congress of AEEH
AEEH (Madrid, Espanha)
2023/01/28 Cellular and molecular mechanisms of alcohol-induced liver injury Joint Meeting APEF-AEEH on Alcohol-related Liver Disease
APEF (Porto, Portugal)
2023/01/26 Deciphering the complexity of cholangiocarcinoma tumors: novel insights in liquid biopsy, pathogenesis and therapeutic targets CIC bioGUNE Seminar Series
CIC Biogune (Bilbao, Espanha)
2022/12/16 Extracellular Vesicles 4th Meeting of Translational Hepatology – Liver Cancer
AEEH (Santiago de Compostela, Espanha)
2022/10/11 miRNAs as modulators of NAFLD pathogenesis and progression towards liver cancer UEG Week 2022
UEG (Vienna, Áustria)
2022/10/11 A role for miR-21 in non-alcoholic fatty liver disease pathogenesis UEG Week 2022
UEG (Vienna, Áustria)
2022/09/21 Next-generation biomarkers for cholangiocarcinoma PhD Course on Biomarkers and Advanced Technologies
iMed.ULisboa (Lisboa, Portugal)
2022/06/21 Novel strategies for biomarker discovery in PSC-CCA IPSCSG Biennial Meeting
IPSCSG (London, Reino Unido)
2022/05/20 Polycystic liver diseases XXI Jornadas de Avances en Hepatologia
University of Malaga (Malaga, Espanha)
2022/05/13 Role of the transcription factor KLF5 in the etiopathogenesis of CCA: new diagnostic, prognostic and therapeutic strategy AMMF 2022 European Cholangiocarcinoma Conference
AMMF (London, Reino Unido)
2022/03/15 A role for miR-21 in non-alcoholic fatty liver disease pathogenesis SEBBM Seminars
SEBBM (Espanha)
2021/12/11 Etiopathogenesis of primary biliary cholangitis: myths and facts Jornadas de Otoño AEEH
AEEH (Malaga, Espanha)
2021/09/23 Next-generation biomarkers for cholangiocarcinoma 27th Italian National Congress of Digestive Diseases
FISMAD (Itália)
2021/03/08 Beating cancer by 2030: mission impossible?
Belgian Nuclear Research Center (SCK CEN) (Bélgica)
2020/12 Perfiles especificos de RNA en vesiculas extracelulares de suero y orina de pacientes con colangiocarcinoma que imitan el tejido tumoral y la expresión celular: nuevo enfoque de biopsia liquida 23rd Annual Meeting of the Gastroenterology Spanish Association
AEG (Espanha)
2020/10/12 Talent Pool UEG Week Virtual 2020.
United European Gastroenterology (UEG)
2020/10/11 Liver miRNA-222-3p is activated in non-alcoholic steatohepatitis and ablation prevents disease pathogenesis. UEG Week Virtual 2020.
United European Gastroenterology (UEG)
2020/06 Lysyl oxidase shapes physical and metabolic interactions between tumor and stroma in cholangiocarcinoma patients. The International Liver Cancer Association Virtual Congress
The International Liver Cancer Association (ILCA)
2020/06 Os níveis hepáticos de miR-222-3p estão elevados em doentes com fígado gordo não alcoólico e a sua supressão previne a patogénese da doença em murganhos. Semana Digestiva 2020
Sociedade Portuguesa de Gastroenterologia (SPG) (Portugal)
2020/06 TREM2 protects the liver against hepatocellular carcinoma through multifactorial protective mechanisms. 55th The International Liver Congress
European Association for the Study of the Liver (EASL)
2020/06 The anti-inflammatory receptor TREM2 protects the liver from cholestatic injury 55th The International Liver Congress
European Association for the Study of the Liver (EASL)
2020/02 Nuevos biomarcadores proteicos en vesículas extracelulares de suero para el diagnóstico del colangiocarcinoma (CCA) en pacientes con colangitis esclerosante primaria (PSC) XLV Congreso Anual de la Asociación Española para el Estudio del Hígado (AEEH)
Asociación Española para el Estudio del Hígado (AEEH) (Espanha)
2020/02 Proteostasis improvement in cystic cholangiocytes alleviates endoplasmic reticulum stress and halts polycystic liver disease XLV Congreso Anual de la Asociación Española para el Estudio del Hígado (AEEH)
Asociación Española para el Estudio del Hígado (AEEH) (Espanha)
2020/02 Serum and urine extracellular vesicles contain specific RNAs with diagnostic capacity for cholangiocarcinoma, being possibly involved in disease pathogenesis Liver Cancer Summit
European Association for the Study of the Liver (EASL) (Prague, República Checa)
2020/02 Hepatic RIP3 signalling differentially modulates lipid metabolism and inflammation/carcinogenesis in non-alcoholic steatohepatitis Liver Cancer Summit
European Association for the Study of the Liver (EASL) (Prague, República Checa)
2020/02 miR-21 is increased in patients with NASH-associated HCC and contributes to hepatocarcinogenesis in mice with NAFLD. Liver Cancer Summit
European Association for the Study of the Liver (EASL) (Prague, República Checa)
2019/11/11 Novel receptors in Liver disease “Early Morning Workshop”, at The Liver Meeting
American Association for the Study of Liver Diseases (AASLD) (Boston, Estados Unidos)
2019/11 TREM2 protects the liver against hepatocellular carcinoma through multifactorial protective mechanisms Congress of the Basque-Navarra Society of Digestive Pathology (SVNPD)
Basque-Navarra Society of Digestive Pathology (SVNPD) (Espanha)
2019/11 Obese patients carrying NAFLD-associated genetic variants present specific serum and liver lipidomic profiles: identification of a lipidomic signature in serum to estimate the liver fat content. The Liver Meeting
American Association for the Study of Liver Diseases (AASLD) (Boston, Estados Unidos)
2019/10/04 Liquid Biopsy 1ª Reunión de Hepatologia Traslacional: Status Quo y nuevos horizontes en el estudio del hígado
Asociación Española para el Estudio del Hígado (AEEH) (Espanha)
2019/10 miR-21 is increased in experimental and human NASH-associated HCC, contributing to hepatocarcinogenesis. 27th United European Gastroenterology Week
United European Gastroenterology (UEG) (Espanha)
2019/10 New synthetic conjugates of ursodeoxycholic acid inhibit cystogenesis in experimental models of polycystic liver disease 1ª Reunión de Hepatologia Traslacional: Status Quo y nuevos horizontes en el estudio del hígado
Asociación Española para el Estudio del Hígado (AEEH) (Espanha)
2019/09/12 Beating cancer by 2030: mission impossible? A COST Connect report on the future of European Cancer Research COST Action 18122- EURO-CHOLANGIO-NET Working Group Set-up Meeting
EURO-CHOLANGIO-NET COST Action 18122 (Malta)
2019/04 New synthetic conjugates of ursodeoxycholic acid inhibit hepatorenal cystogenesis in experimental models of polycystic liver disease 54th The International Liver Congress
European Association for the Study of the Liver (EASL) (Áustria)
2019/04 Activation of the miR-34a/SIRT1:AMPK axis contributes for insulin resistance and mitochondrial dysfunction in the NAFLD muscle 54th The International Liver Congress
European Association for the Study of the Liver (EASL) (Áustria)
2019/02 New synthetic conjugates of ursodeoxycholic acid inhibit hepatorenal cystogenesis in experimental models of polycystic liver disease 44th Annual Congress of the Spanish Association for the Study for the Liver (AEEH)
Asociación Española para el Estudio del Hígado (AEEH) (Espanha)
2019/02 RIP3-dependent signalling exerts divergent effects on liver steatosis and carcinogenesis in experimental non-alcoholic fatty liver disease 3rd EASL HCC Summit
European Association for the Study of the Liver (EASL) (Portugal)
2018/10 Serum and urine extracellular vesicles contain mRNA biomarkers for primary sclerosing cholangitis (PSC) and cholangiocarcinoma (CCA) 26th United European Gastroenterology Week
United European Gastroenterology (UEG) (Áustria)
2018/10 Muscle miR-34a is activated during NAFLD progression, promoting insulin resistance and mitochondrial dynamics dysfunction 26th United European Gastroenterology Week
United European Gastroenterology (UEG) (Áustria)
2018/06 Metabolic regulation of neurogenesis by gut microbiome during nonalcoholic steatohepatitis. Targeting Mitochondria 2018
(Alemanha)
2018/06 A ativação do miR-34a promove disfunção da dinâmica mitocondrial no músculo de doentes com fígado gordo não alcoólico Semana Digestiva 2018
Sociedade Portuguesa de Gastroenterologia (SPG) (Portugal)
2018/04 The role of necroptosis in non-alcoholic fatty liver disease-related carcinogenesis 19th biennial meeting for the Society for Free Radical Research International (SFRRI)
Society for Free Radical Research International (SFRRI) (Portugal)
2018/04 Deregulation of small intestine permeability by miRNA-21 in liver disease. 19th biennial meeting for the Society for Free Radical Research International (SFRRI)
Society for Free Radical Research International (SFRRI) (Portugal)
2018/01/26 A role for miR-21 in non-alcoholic fatty liver disease pathogenesis Seminar
Biodonostia Health Research Institute (Espanha)
2017 miR-21 ablation and obeticholic acid ameliorate non-alcoholic steatohepatitis in mice. Keystone symposia: Bile Acid Receptors as Signal Integrators in Liver and Metabolism
Keystone (California, Estados Unidos)
2016/12 Multi-targeting of nuclear receptors halts NAFLD progression in mice XIX National Congress of Biochemistry
Sociedade Portuguesa de Bioquimica (Portugal)
2016/12 Necroptosis is triggered in human and experimental cholestasis XIX National Congress of Biochemistry
Sociedade Portuguesa de Bioquimica (Portugal)
2016/10 Improving metabolic parameters in NAFLD by targeting nuclear receptors 24th United European Gastroenterology Week
United European Gastroenterology (UEG) (Áustria)
2016/10 Activation of necroptosis in human and experimental cholestasis 24th United European Gastroenterology Week
United European Gastroenterology (UEG) (Áustria)
2016/07 Multi-targeting of nuclear receptors ameliorates NAFLD pathogenesis in mice VIII iMed.ULisboa Postgraduate Students Meeting
iMed.ULisboa (Portugal)
2016/06 Ativação de recetores nucleares no tratamento do fígado gordo não alcoólico Semana Digestiva 2016
Sociedade Portuguesa de Gastroenterologia (SPG) (Portugal)
2016/06 A ativação do miRNA-34a contribui para a disfunção mitocondrial e resistência à insulina em modelos experimentais de fígado gordo não alcoólico. Semana Digestiva 2016
Sociedade Portuguesa de Gastroenterologia (SPG) (Portugal)
2016/06 A necroptose na colestase aguda e crónica Semana Digestiva 2016
Sociedade Portuguesa de Gastroenterologia (SPG) (Portugal)
2015/11 Inhibition of NF-kB by deoxycholic acid induces miR-21/PDCD4-dependent hepatocelular apoptosis The Liver Meeting
American Association for the Study of Liver Diseases (AASLD) (San francisco, Estados Unidos)
2015/10 Dual targeting of microRNA-21 and FXR ameliorates NAFLD pathogenesis in mice 23rd United European Gastroenterology Week, Barcelona
United European Gastroenterology (UEG) (Espanha)
2015/10 Profiling and modulation of skeletal muscle microRNAs in non-alcoholic fatty liver disease patients and in insulin-resistant C2C12 muscle cells 23rd United European Gastroenterology Week, Barcelona
United European Gastroenterology (UEG) (Espanha)
2015/10 The dual role of necroptosis in cholestasis 23rd Conference of the European Cell Death Organization-Death pathways and beyond
European Cell Death Organization (Suiça)
2015/06 A modulação simultânea do FXR e miR-21 inibe a esteatose e inflamação em ratinhos com esteatohepatite Semana Digestiva 2015
Sociedade Portuguesa de Gastroenterologia (SPG) (Portugal)
2015/06 Papel da necroptose na colestase em ratinhos e em doentes Semana Digestiva 2015
Sociedade Portuguesa de Gastroenterologia (SPG) (Portugal)
2015/06 Alteração dos perfis de microRNAs no músculo esquelético de doentes com fígado gordo não-alcoólico e papel protetor do TUDCA Semana Digestiva 2015
Sociedade Portuguesa de Gastroenterologia (SPG) (Portugal)
2015/02 Efeito sinergético do silenciamento do miR-21 e ativação do FXR na inibição da patogénese do fígado gordo não-alcoólico em ratinhos Congresso Português de Hepatologia 2015
Associação Portuguesa para o Estudo do Figado (APEF) (Portugal)
2015/02 A necroptose está ativada na colestase Congresso Português de Hepatologia 2015
Associação Portuguesa para o Estudo do Figado (APEF) (Portugal)
2014/12 DCA-induced oxidative stress and NF-kB inhibition activates the miR-21/PDCD4 pro-apoptotic pathway in primary rat hepatocytes XVIII Congress of the Portuguese Biochemical Society
Sociedade Portuguesa de Bioquimica (Portugal)
2014/11 Deoxycholic acid triggers primary rat hepatocyte apoptosis in a dose-dependent manner by hampering caspase-2/NF-kB-associated activation of miRNA-21. The Liver Meeting
American Association for the Study of Liver Diseases (AASLD) (Estados Unidos)
2014/10 Role of necroptosis in murine models of bile acid toxicity 22nd United European Gastroenterology Week
United European Gastroenterology (UEG) (Áustria)
2014/10 Deoxycholic acid induces miR-21/PDCD4-dependent cytotoxicity by hampering NF-kB survival signaling in primary rat hepatocytes 22nd United European Gastroenterology Week, Vienna, Austria
United European Gastroenterology (UEG) (Portugal)
2014/02 Modulação da actividade do NF-kB pelo ácido desoxicólico no fígado de rato: efeitos na via do miRNA-21, apoptose e inflamação Congresso Português de Hepatologia 2014
Associação Portuguesa para o Estudo do Figado (APEF) (Portugal)
2013/07 JNK1 is a key target of deoxycholic acid in activating the miR-34a/SIRT1/p53 pro-apoptotic pathway. V iMed.UL Postgraduate Students Meeting
iMed.ULisboa (Portugal)
2013/04 JNK1-Dependent modulation of miR-34a contributes to apoptosis induced by deoxycholic acid in primary rat hepatocytes 48th International Liver Congress
European Association for the Study of the Liver (EASL) (Países Baixos)
2012/10 miR-34a/SIRT1/p53 signaling is activated in human non-alcoholic fatty liver disease and target by ursodeoxycholic acid in the rat liver via inhibition of p53 transactivation 20th United European Gastroenterology Week
United European Gastroenterology (UEG) (Países Baixos)

Orientação

Título / Tema
Papel desempenhado 		Curso (Tipo)
Instituição / Organização
2024/01/01 - Atual Novel epigenetic players in the diagnosis, pathogenesis and treatment of non-alcoholic fatty liver disease-associated cholangiocarcinoma
Orientador de Santiago Iturbe Rey
Biogipuzkoa Health Research Institute, Espanha
2023 - Atual Exosomal microRNAs in liver-muscle intercommunication during non-alcoholic fatty liver disease pathogenesis
Coorientador
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
2022/01/01 - Atual Role of mitochondrial dysfunction and autophagy in the pathogenesis of Primary Biliary Cholangitis (PBC)
Coorientador
Biodonostia Instituto de Investigación Sanitaria, Espanha
2022/01/01 - Atual Nueva estrategia no invasiva basada en metabolómica para la predicción del pronóstico de pacientes con colangitis esclerosante primaria (CEP) y el diagnóstico temprano del colangiocarcinoma (CCA)
Coorientador
Biodonostia Instituto de Investigación Sanitaria, Espanha
2019 - 2023/02/24 Role of transcription factor KLF5 in the etiopathogenesis and chemoresistance of cholangiocarcinoma: novel diagnostic, prognostic and therapeutic strategy
Coorientador de Ana Landa
Biodonostia Instituto de Investigación Sanitaria, Espanha
2019/01/01 - 2022/11/07 Role of the transcription factor KLF15 in the etiopathogenesis of biliary cancer: new diagnostic, prognostic and therapeutic strategy
Coorientador
Biodonostia Instituto de Investigación Sanitaria, Espanha
2021 - 2022/06/17 Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Coorientador
Biodonostia Instituto de Investigación Sanitaria, Espanha
2018/01/01 - 2022/01/28 Cholangiocarcinoma biomarkers in biofluid extracellular vesicles: a new liquid biopsy strategy
Coorientador
Biodonostia Instituto de Investigación Sanitaria, Espanha
2021/03/01 - 2021/09/13 Role of mitochondrial dysfunction and autophagy in the pathogenesis of primary biliary cholangitis
Coorientador
Biodonostia Instituto de Investigación Sanitaria, Espanha
2020/03 - 2020/11/18 Role of the posttranslational modifications in the etiopathogenesis of cholangiocarcinoma: new diagnostic, prognostic and therapeutic strategy
Coorientador
Biodonostia Instituto de Investigación Sanitaria, Espanha

Organização de evento

Nome do evento
Tipo de evento (Tipo de participação) 		Instituição / Organização
2022/12/16 - 2022/12/17 4th Meeting of Translational Hepatology - Liver Cancer (2022/12/16 - 2022/12/17)
Conferência (Membro da Comissão Organizadora)
 Asociación Española Para el Estudio del Hígado, Espanha
2015/01 - 2016/12 VII iMed.ULisboa Post-graduate Students Meeting (2015/07 - 2015/07)
Congresso (Membro da Comissão Organizadora)
 Universidade de Lisboa Faculdade de Farmácia, Portugal
2015/01 - 2016/01 VIII iMed.ULisboa Post-graduate Students Meeting (2016/07 - 2016/07)
Congresso (Membro da Comissão Organizadora)
 Universidade de Lisboa Faculdade de Farmácia, Portugal

Participação em evento

Descrição da atividade
Tipo de evento 		Nome do evento
Instituição / Organização
2020/10/13 - 2020/10/13 UEG Young GI Mentoring Program: Liver
Encontro
 UEG Week Virtual 2020
United European Gastroenterology, Áustria
2020/10/12 - 2020/10/12 UEG Young GI CV Check
Encontro
 UEG Week Virtual 2020
United European Gastroenterology, Áustria
2020/10/11 - 2020/10/11 UEG Young GI Mentoring Program: Basic Science
Encontro
 UEG Week Virtual 2020
United European Gastroenterology, Áustria
2019/05/21 - 2019/05/22 COST Connect: a meeting getting together all the cancer-related COST actions in Europe to discuss the future of cancer management and treatment for the next decade
Oficina (workshop)
 Beating cancer by 2030: mission impossible?

Júri de grau académico

Tema
Tipo de participação 		Nome do candidato (Tipo de grau)
Instituição / Organização
2023/11/23 Paisaje epigenético y epitranscriptómico en la enfermedad hepática crónica por depósito de grasa y el hepatoblastoma: análisis de la expresión de los genes involucrados.
Arguente
 José María Herranz Alzueta (Doutoramento)
Universidad de Navarra, Espanha
2022/11/29 The role of necroptotic extracellular vesicles in NAFLD pathogenesis
Arguente
 Gonçalo Marques de Sousa Campino (Mestrado)
Biodonostia Instituto de Investigación Sanitaria, Espanha
2021/12/21 Targeting the adipose tissue to treat fatty liver: role of TGR5
Arguente principal
 Daniela Silva (Mestrado)
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
2021/09/22 Extracellular vesicles in cancer: therapeutic implications
Arguente principal
 Luisa Bastos (Mestrado)
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
2021/01/29 Serum miRNA Profiling for the Early-Diagnosis of Distal Cholangiocarcinoma
Arguente principal
 André Filipe Agostinho Tomás (Mestrado)
Universidade de Lisboa Faculdade de Farmácia, Portugal
2020/11/19 New drugs for the treatment of liver diseases: advances on treatments for hepatocellular carcinoma
Arguente principal
 Simaura Alexandra Marques Faria (Mestrado)
Universidade de Lisboa Faculdade de Farmácia, Portugal

Arbitragem científica em conferência

Nome da conferência Local da conferência
2020/01/01 - 2021/12/31 UEG Week United European Gastroenterology (UEG)

Arbitragem científica em revista

Nome da revista (ISSN) Editora
2021 - Atual Biology
2021 - Atual Current Oncology
2020/12 - Atual Frontiers in Pharmacology
2020/04 - Atual Cancers
2020 - Atual Cells
2020 - Atual World Journal of Gastroenterology
2020 - Atual Oncotargets and Therapy
2020 - Atual UEG Journal
2020 - Atual Microorganisms
2020 - Atual World Journal of Hepatology
2020 - Atual World Journal of Hepatology
2020 - Atual International Journal of Hepatology
2020 - Atual Frontiers in Medicine
2020 - Atual International Journal of General Medicine
2020 - Atual Cellular and Molecular Gastroenterology and Hepatology
2020 - Atual Metabolites
2020 - Atual Therapeutic Advances in Gastroenterology
2020 - Atual Journal of Hepatocellular Carcinoma
2020 - Atual International Journal of Molecular Sciences
2019 - Atual Theranostics
2019 - Atual Hepatobiliary Surgery and Nutrition
2019 - Atual Experimental and Molecular Medicine
2019 - Atual Cancer Management and Research
2018 - Atual Cell Death & Disease
2018 - Atual BBA Molecular Basisi of Disease
2018 - Atual Cellular Physiology and Biochemistry
2018 - Atual GE Liver
2018 - Atual PLoS One
2018 - Atual Liver International
2018 - Atual REED
2018 - Atual Journal of Physiology and Biochemistry
2017 - Atual Scientific Reports
2017 - Atual Journal of Cellular and Molecular Medicine
2017 - Atual Molecular and Cellular Endocrinology
2015 - Atual Biomolecules

Curso / Disciplina lecionado

Disciplina Curso (Tipo) Instituição / Organização
2019/12 - Atual Bioinformartics Biomedical Investigation (Master) Universidad de Navarra, Espanha
2015/12 - 2016/12 Cell Signalling Biopharmaceutical Sciences (Mestrado) Universidade de Lisboa Faculdade de Farmácia, Portugal

Membro de associação

Nome da associação Tipo de participação
2021/09/01 - Atual Ikerbasque
2021 - Atual AEEH
2021 - Atual Spanish Association of Biochemistry and Molecular Biology (SEBBM)
2020/03 - Atual CIBERehd (ISCIII)
2018/04 - Atual European Network for the Study of Cholangiocarcinoma (ENS-CCA)
2014/04 - Atual European Association for the Study of the Liver (EASL)

Membro de comissão

Descrição da atividade
Tipo de participação 		Instituição / Organização
2020/01/01 - 2021/12/31 UEG Young Talent Group (YTG)
Membro
 United European Gastroenterology, Áustria

Revisão ad hoc de artigos em revista

Nome da revista (ISSN) Editora
2022/02 - Atual Journal of Hepatology

Tutoria

Tópico Nome do aluno
2018/11/25 - 2019/01/06 Role of miR-506 in the regulation of the liver- and immunophenotype in primary biliary cholangitis Mariana Esteves Araújo
2018/07/01 - 2018/08/31 Role of KLF5 in the pathogenesis of Cholangiocarcinoma Leyre Ayerra
2018/06/01 - 2018/06/30 Role of KLF5 in the pathogenesis of Cholangiocarcinoma Jon Matas
2017/09 - 2018/03 Targeting bile acid-activated receptors for preventing non-alcoholic fatty liver disease progression Mohammad Mohabbulla Mohib Shuvro
2017/08 - 2018/03 Triple targeting of nuclear receptors for the treatment of non-alcoholic fatty liver disease Tawhidul Islam Srabon
Distinções

Prémio

2024 AEEH Rising Star 2024
Asociación Española Para el Estudio del Hígado, Espanha
2023 Best Basic Science Poster
Asociación Española Para el Estudio del Hígado, Espanha
2023 Best Oral Communication
Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas, Espanha
2023 Best Poster Presentation
United European Gastroenterology, Áustria
2023 Best Poster
2022 UEG Rising Star 2022
United European Gastroenterology, Áustria
2022 Cells 2022 Young Investigator Award
Cells MDPI, Suiça
2021 2020 Outstanding Reviewer Award
Cancers, Suiça
2019 Early Career Investigator in Basic Science Award
American Association for the Study of Liver Diseases, Estados Unidos

Título

2021 Ikerbasque Research Fellow
Ikerbasque, Espanha
2019 Sara Borrell Investigator
Instituto de Salud Carlos III, Espanha
2019 Juan de la Cierva Post-doctoral Fellowship

Outra distinção

2021 Young Investigator Bursary (Registration Bursary)
European Association for the Study of the Liver, Suiça
2020 Young Investigator Bursary (Full Bursary)
European Association for the Study of the Liver, Suiça
2019 Young Investigator Bursary (Full Bursary) to “EASL HCC Summit”, Lisbon, Portugal
2019 Seal of Excellence
Horizon 2020, Bélgica
2019 Young Investigator Bursary (Full Bursary)
European Association for the Study of the Liver, Suiça
2019 Travel Grant
United European Gastroenterology, Áustria
2018 Young Investigator Bursary (Full Bursary) to “EASL HCC Summit”, Geneva, Switzerland
2018 Travel Grant to “United European Gastroenterology (UEG) Week 2018”, Vienna, Austria
2018 Best Oral Communication at 26th UEGW, Vienna, Austria
2017 Young Investigator Bursary (Registration Bursary) to “EASL HCC Summit”, Geneva, Switzerland
2017 Young Investigator Bursary (Registration Bursary) to “The International Liver Congress 2017”, Amsterdam, The Netherlands
2017 Young Investigator Bursary (Full Bursary) to “EASL NAFLD Summit”, Rome, Italy
2016 IJMS Junior Scientist Travel Award 2016
2016 Young Investigator Bursary (Registration Bursary) to “The International Liver Congress 2016”, Barcelona, Spain
2016 Young Investigator Bursary (Full Bursary) to “EASL Monothematic Conference: Liver fibrosis – the next goal of targeted therapy?”, Porto, Portugal
2016 Best Oral Communication in Semana Digestiva 2016, Algarve, Portugal
2016 Travel Grant to “UEG Week 2016”, Vienna, Austria
2015 Young Investigator Bursary (Full Bursary) to “The International Liver Congress 2015”, Vienna, Austria
2015 Young Investigator Bursary (Full Bursary) to “EASL Monothematic Conference: Microbiota, Metabolism and NAFLD”, Innsbruck, Austria
2015 Travel Grant to “UEG Week 2015”, Barcelona, Spain
2015 Young Investigator Award
2015 Presidential Poster of Distinction (top 10% of scored abstracts) at the Liver Meeting 2015, San Francisco, USA
2014 Young Investigator Bursary (Full Bursary) to “The International Liver Congress 2014”, London, UK
2014 Travel Grant to “UEG Week”, Vienna, Austria
2014 <b>National Scholar Award</b> (selected among all abstracts submitted from Portugal) at 22nd United European Gastroenterology Week (UEGW), Vienna, Austria
2013 Ph.D. Fellowship (SFRH/BD/88212/2012)
Fundação para a Ciência e a Tecnologia, Portugal